US8318934B2 - Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes - Google Patents
Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes Download PDFInfo
- Publication number
- US8318934B2 US8318934B2 US12/680,137 US68013708A US8318934B2 US 8318934 B2 US8318934 B2 US 8318934B2 US 68013708 A US68013708 A US 68013708A US 8318934 B2 US8318934 B2 US 8318934B2
- Authority
- US
- United States
- Prior art keywords
- general formula
- compound
- oxathiolane
- solvent
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 230000008569 process Effects 0.000 title claims abstract description 60
- -1 2-substituted 4-substituted 1,3-oxathiolanes Chemical class 0.000 title claims abstract description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 307
- 150000001875 compounds Chemical class 0.000 claims description 161
- 238000001953 recrystallisation Methods 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000002904 solvent Substances 0.000 claims description 62
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 38
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 32
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 claims description 31
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000010899 nucleation Methods 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 0 [1*]C1COC(CO)S1 Chemical compound [1*]C1COC(CO)S1 0.000 description 64
- 238000003756 stirring Methods 0.000 description 40
- 239000000047 product Substances 0.000 description 39
- 125000002877 alkyl aryl group Chemical group 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 229910052799 carbon Inorganic materials 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 32
- 230000003287 optical effect Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 11
- XQBRZRVPNRAYOW-RTBURBONSA-N [(2r,4r)-4-(4-benzamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C([C@@H]1OC[C@@H](S1)N1C=CC(=NC1=O)NC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 XQBRZRVPNRAYOW-RTBURBONSA-N 0.000 description 11
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- XBDUZBHKKUFFRH-UHFFFAOYSA-N n-(2-oxo-1h-pyrimidin-6-yl)benzamide Chemical compound OC1=NC=CC(NC(=O)C=2C=CC=CC=2)=N1 XBDUZBHKKUFFRH-UHFFFAOYSA-N 0.000 description 11
- PCXPPEVXIKTQGP-UHFFFAOYSA-N 1,3-oxathiolan-2-ylmethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1OCCS1 PCXPPEVXIKTQGP-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 6
- PCXPPEVXIKTQGP-SNVBAGLBSA-N [(2r)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC[C@@H]1OCCS1 PCXPPEVXIKTQGP-SNVBAGLBSA-N 0.000 description 6
- LSOHGQXOSJAKNH-HQNRFAHOSA-N [(2r)-3-oxo-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC[C@@H]1OCCS1=O LSOHGQXOSJAKNH-HQNRFAHOSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- ZTRXFCGYDLPIDD-UHFFFAOYSA-N 4-amino-1-benzoylpyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C(=O)C1=CC=CC=C1 ZTRXFCGYDLPIDD-UHFFFAOYSA-N 0.000 description 4
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 4
- XQBRZRVPNRAYOW-OALUTQOASA-N [(2s,4s)-4-(4-benzamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C([C@H]1OC[C@H](S1)N1C=CC(=NC1=O)NC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 XQBRZRVPNRAYOW-OALUTQOASA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 4
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- LSOHGQXOSJAKNH-UHFFFAOYSA-N (3-oxo-1,3-oxathiolan-2-yl)methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1OCCS1=O LSOHGQXOSJAKNH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IJCKBIINTQEGLY-UHFFFAOYSA-N N(4)-acetylcytosine Chemical compound CC(=O)NC1=CC=NC(=O)N1 IJCKBIINTQEGLY-UHFFFAOYSA-N 0.000 description 2
- ABHKTSYMVSJHBR-UTGNMFGYSA-N NC1=NC(=O)N([C@H]2CO[C@@H](CO)S2)C=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 Chemical compound NC1=NC(=O)N([C@H]2CO[C@@H](CO)S2)C=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 ABHKTSYMVSJHBR-UTGNMFGYSA-N 0.000 description 2
- QSUWVYPUAUUUIV-UHFFFAOYSA-N O=C(NC1=NC(=O)N(C2COC(CO)S2)C=C1)C1=CC=CC=C1 Chemical compound O=C(NC1=NC(=O)N(C2COC(CO)S2)C=C1)C1=CC=CC=C1 QSUWVYPUAUUUIV-UHFFFAOYSA-N 0.000 description 2
- RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XQBRZRVPNRAYOW-GGYWPGCISA-N [(2S)-4-(4-benzamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@H]1OCC(S1)N1C(=O)N=C(NC(C2=CC=CC=C2)=O)C=C1 XQBRZRVPNRAYOW-GGYWPGCISA-N 0.000 description 2
- XQBRZRVPNRAYOW-MUMRKEEXSA-N [(2r)-4-(4-benzamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C([C@@H]1OCC(S1)N1C=CC(=NC1=O)NC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 XQBRZRVPNRAYOW-MUMRKEEXSA-N 0.000 description 2
- SAAYTTIZMJCRNY-QZTJIDSGSA-N [(2r,4r)-4-(4-benzamido-5-fluoro-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C([C@@H]1OC[C@@H](S1)N1C=C(C(=NC1=O)NC(=O)C=1C=CC=CC=1)F)OC(=O)C1=CC=CC=C1 SAAYTTIZMJCRNY-QZTJIDSGSA-N 0.000 description 2
- PCXPPEVXIKTQGP-JTQLQIEISA-N [(2s)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC[C@H]1OCCS1 PCXPPEVXIKTQGP-JTQLQIEISA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000005272 metallurgy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- KCUPNJVFRBGYFW-UHFFFAOYSA-N n-(5-fluoro-2-oxo-1h-pyrimidin-6-yl)benzamide Chemical compound C1=NC(=O)NC(NC(=O)C=2C=CC=CC=2)=C1F KCUPNJVFRBGYFW-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPKYQKSUOMFMRA-SWRRTXJRSA-N *.*.*.O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 Chemical compound *.*.*.O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 FPKYQKSUOMFMRA-SWRRTXJRSA-N 0.000 description 1
- XWQCBWZUWMHWRX-UHFFFAOYSA-N 1,3-oxathiolane 3-oxide Chemical compound O=S1CCOC1 XWQCBWZUWMHWRX-UHFFFAOYSA-N 0.000 description 1
- QNNPPEKCYFEVCF-UHFFFAOYSA-N 2-methyl-1,3-oxathiolane Chemical compound CC1OCCS1 QNNPPEKCYFEVCF-UHFFFAOYSA-N 0.000 description 1
- RYMCFYKJDVMSIR-BQBZGAKWSA-N 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1S[C@@H](CO)OC1 RYMCFYKJDVMSIR-BQBZGAKWSA-N 0.000 description 1
- ZOFBCDTXKMWTON-NBSXEKEZSA-N C.O=C(CC1=NC(=O)N([C@@H]2CO[C@H](CO)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](CO)S2)C=C1)C1=CC=CC=C1 Chemical compound C.O=C(CC1=NC(=O)N([C@@H]2CO[C@H](CO)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](CO)S2)C=C1)C1=CC=CC=C1 ZOFBCDTXKMWTON-NBSXEKEZSA-N 0.000 description 1
- PBZUFQSTUUSBBV-RKWHWOPTSA-N CC(=O)NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1.CC(=O)NC1=NC(=O)NC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1 Chemical compound CC(=O)NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1.CC(=O)NC1=NC(=O)NC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1 PBZUFQSTUUSBBV-RKWHWOPTSA-N 0.000 description 1
- OHMIMBKZOKJZCT-AYXDDKCWSA-N CC(C)[Si](OC[C@@H]1OC[C@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1)(C(C)C)C(C)C.CC(C)[Si](OC[C@H]1OC[C@@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1)(C(C)C)C(C)C Chemical compound CC(C)[Si](OC[C@@H]1OC[C@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1)(C(C)C)C(C)C.CC(C)[Si](OC[C@H]1OC[C@@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1)(C(C)C)C(C)C OHMIMBKZOKJZCT-AYXDDKCWSA-N 0.000 description 1
- YLESPRXWKMPPNQ-WQPPGPSSSA-N CC[C@@H]1OC[C@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@@H]1OC[C@H](N2C=CC(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@H]1OC[C@@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@H]1OC[C@@H](N2C=CC(CC(=O)C3=CC=CC=C3)=NC2=O)S1 Chemical compound CC[C@@H]1OC[C@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@@H]1OC[C@H](N2C=CC(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@H]1OC[C@@H](N2C=C(F)C(CC(=O)C3=CC=CC=C3)=NC2=O)S1.CC[C@H]1OC[C@@H](N2C=CC(CC(=O)C3=CC=CC=C3)=NC2=O)S1 YLESPRXWKMPPNQ-WQPPGPSSSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- ABHKTSYMVSJHBR-UKSBNGCBSA-N NC1=NC(=O)N([C@@H]2CO[C@H](CO)S2)C=C1.O=C(NC1=NC(=O)N([C@@H]2CO[C@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 Chemical compound NC1=NC(=O)N([C@@H]2CO[C@H](CO)S2)C=C1.O=C(NC1=NC(=O)N([C@@H]2CO[C@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 ABHKTSYMVSJHBR-UKSBNGCBSA-N 0.000 description 1
- RYUNXPYIMFTFAF-UHFFFAOYSA-N O=C(C1=CC=CC=C1)OC[S+]1COCC1 Chemical compound O=C(C1=CC=CC=C1)OC[S+]1COCC1 RYUNXPYIMFTFAF-UHFFFAOYSA-N 0.000 description 1
- FBUKNXPCBOPVNO-BQLNUNHXSA-N O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 Chemical compound O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 FBUKNXPCBOPVNO-BQLNUNHXSA-N 0.000 description 1
- CPBLFNJUIZFDEX-PIUXOGMSSA-N O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 Chemical compound O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1 CPBLFNJUIZFDEX-PIUXOGMSSA-N 0.000 description 1
- YPQKGEVJTBUKRE-BLIMTTPQSA-N O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1 Chemical compound O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1 YPQKGEVJTBUKRE-BLIMTTPQSA-N 0.000 description 1
- HCRIFKIIOHOFHL-PZWDBZHRSA-N O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1 Chemical compound O=C(NC1=NC(=O)N([C@@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1.O=C(NC1=NC(=O)N([C@H]2CO[C@@H](COC(=O)C3=CC=CC=C3)S2)C=C1F)C1=CC=CC=C1 HCRIFKIIOHOFHL-PZWDBZHRSA-N 0.000 description 1
- SANNPGRDQKLECS-FVVYACKOSA-N O=C(NC1=NC(=O)N([C@@H]2CO[C@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(OC[C@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 Chemical compound O=C(NC1=NC(=O)N([C@@H]2CO[C@H](COC(=O)C3=CC=CC=C3)S2)C=C1)C1=CC=CC=C1.O=C(OC[C@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 SANNPGRDQKLECS-FVVYACKOSA-N 0.000 description 1
- GGBZNNAKAYOXSQ-NTXTZHDZSA-N O=C(OC[C@@H]1CCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 Chemical compound O=C(OC[C@@H]1CCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 GGBZNNAKAYOXSQ-NTXTZHDZSA-N 0.000 description 1
- QYVVNBQHBRDHCK-AQBBGWCASA-N O=C(OC[C@@H]1OCCS1)C1=CC=CC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1 Chemical compound O=C(OC[C@@H]1OCCS1)C1=CC=CC=C1.O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1 QYVVNBQHBRDHCK-AQBBGWCASA-N 0.000 description 1
- ORPIAKKJYYMDGV-FTYBWHBYSA-N O=C(OC[C@@H]1OCCS1)C1=CC=CC=C1.O=C(OC[C@H]1OCCS1)C1=CC=CC=C1 Chemical compound O=C(OC[C@@H]1OCCS1)C1=CC=CC=C1.O=C(OC[C@H]1OCCS1)C1=CC=CC=C1 ORPIAKKJYYMDGV-FTYBWHBYSA-N 0.000 description 1
- UXXZJVCHXVEMAT-KHATYMAESA-N O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C(F)=CN1 Chemical compound O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C(F)=CN1 UXXZJVCHXVEMAT-KHATYMAESA-N 0.000 description 1
- IUFYBVBBYSIVFY-KHATYMAESA-N O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 Chemical compound O=C(OC[C@@H]1OCCS1=O)C1=CC=CC=C1.O=C1N=C(NC(=O)C2=CC=CC=C2)C=CN1 IUFYBVBBYSIVFY-KHATYMAESA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SAAYTTIZMJCRNY-QRWMCTBCSA-N [(2R)-4-(4-benzamido-5-fluoro-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@@H]1OCC(S1)N1C(=O)N=C(NC(C2=CC=CC=C2)=O)C(=C1)F SAAYTTIZMJCRNY-QRWMCTBCSA-N 0.000 description 1
- USNVFUNJPFUFQM-HUUCEWRRSA-N [(2r,4r)-4-(4-acetamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@@H]1S[C@H](COC(=O)C=2C=CC=CC=2)OC1 USNVFUNJPFUFQM-HUUCEWRRSA-N 0.000 description 1
- LSOHGQXOSJAKNH-VQVVDHBBSA-N [(2s)-3-oxo-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC[C@H]1OCCS1=O LSOHGQXOSJAKNH-VQVVDHBBSA-N 0.000 description 1
- XQBRZRVPNRAYOW-UHFFFAOYSA-N [4-(4-benzamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)NC(=NC1=O)C=CN1C(S1)COC1COC(=O)C1=CC=CC=C1 XQBRZRVPNRAYOW-UHFFFAOYSA-N 0.000 description 1
- SAAYTTIZMJCRNY-UHFFFAOYSA-N [4-(4-benzamido-5-fluoro-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound O=C1N=C(NC(=O)C=2C=CC=CC=2)C(F)=CN1C(S1)COC1COC(=O)C1=CC=CC=C1 SAAYTTIZMJCRNY-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000669 high-field nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivatives thereof of general formula (I):
- the present invention also relates to novel 2-substituted 4-substituted 1,3-oxathiolanes derivatives.
- Classes of compounds known as 2-substituted 4-substituted 1,3-oxathiolanes, in particular derivatives of analogues of pyrimidine nucleosides have been found to have potent antiviral activity.
- these compounds have been found to act as potent inhibitors of HIV-1 replication in T-lymphocytes over a prolonged period of time with less cytotoxic side effects than compounds known in the art (see for example Belleau et. al. (1993) Bioorg. Med. Chem. Lett . Vol. 3, No. 8, 1723-1728).
- These compounds have also been found active against 3TC-resistant HIV strains (see for example Taylor et. al. (2000) Antiviral Chem. Chemother . Vol. 11, No.
- Compounds of the 2-substituted 4-substituted 1,3-oxathiolane family contain two chiral centres.
- Compounds that contain two chiral centres can exist as a mixture of four stereoisomers, where the configuration at the two chiral centres is (R,R) or (R,S) or (S,R) or (S,S).
- the (R,R) and (S,S) forms are known as cis enantiomers as they are non-superimposible mirror images of each other and the (R,S) and (S,R) forms are known as the trans enantiomers for the same reason.
- stereoisomeric forms also known as a chirally pure form. It can be that synthesis of a single stereoisomer can be achieved from a starting material with a single chiral centre in enantiomerically pure form or a suitable intermediate.
- cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane may be produced by the methods described by Mansour et al., “Anti-Human Immunodeficiency Virus and Anti-Hepatitis-B Virus Activities and Toxicities of the Enantiomers of 2′-Deoxy-3′-oxa-4′-thiacytidine and Their 5-Fluoro Analogues in vitro”, J. Med. Chem ., (1995), Vol. 38, No. 1, 1-4, as well as the methods disclosed in U.S. Pat. No.
- compounds or any convenient intermediate may be resolved by enzyme mediated enantioselective catabolism with a suitable enzyme such as cytidine deaminase or selective enzymatic degradation of a suitable derivative (see for example Storer et. al., “The resolution and Absolute Stereochemistry of the Enantiomers of cis 1[2(Hydroxomethyl)-1,3-Oxathiolan-5-Yl)Cytosine (BCH-189): Equipotent Anti-HIV Agents”, Nucleosides & Nucleotides , (1993) 12(2), 225-236).
- a suitable enzyme such as cytidine deaminase or selective enzymatic degradation of a suitable derivative
- WO 2006/096954 discloses a method for the preparation of optically active cis 1,3-oxathiolanes. The method involves, (a) reacting a 1,3-oxathiolane compound in the cis configuration with a chiral acid to produce two diastereomeric salts; (b) recovering one of the two diastereomeric salts; and (c) desalting to remove the chiral acid.
- Preferred chiral acids include (+)-L-tartaric acid, (1R)-( ⁇ )-10-camphorsulfonic acid, ( ⁇ )-2,3-dibenzoyl-tartaric acid or ( ⁇ )-L-malic acid.
- the method also discloses the addition of an achiral acid together with the chiral acid to produce the two diastereomeric salts.
- a disadvantage with the method of WO 2006/096954 is the salt formation step. This step requires the use of chiral acid reagents and in some cases also achiral acids.
- the salt formation step also requires the introduction of a further desalting step to obtain the desired optically active cis product.
- the present inventors have found that by the correct choice of groups R2, R3 and R4, an optically active compound of general formula (II) or (III) may be obtained by selective recrystallisation.
- the present inventors have also found that the recrystallisation solvent of choice is selected on the basis of groups R2, R3 and R4.
- the present invention avoids the salting and desalting steps required by previous methods and provides a simpler, more efficient process to produce optically active cis 1,3-oxathiolanes.
- the invention provides a way of separating an undesired diastereomer such as the trans diastereomer and enhancing the optical purity of the cis isomer by recrystallisation.
- the present invention also provides novel 2-substituted 4-substituted 1,3-oxathiolane derivatives.
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- the present invention provides a compound of general formula (VIII) or (IX):
- the present invention provides a process for producing a compound of general formula (VI) or (VII) from a compound of general formula (VIII) or (IX) respectively, comprising the step of:
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- the present invention provides a process for separating a compound of general formula (II) from a compound of general formula (III) comprising the steps of:
- the present invention advantageously provides a process for obtaining an optically active compound of general formula II or III by selective recrystallisation.
- the compounds of general formula (II) or (III) may be selectively recrystallised from a mixture of the two cis isomers or a mixture of the four stereoisomers, these being the two cis isomers (II) and (III) and the two trans isomers (XI) and (XII) as follows:
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- R6 is phenyl
- R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
- R5 is H or F.
- the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
- TMS trimethylsilyl
- TDPS tert-butyldiphenylsilyl
- TDMS/TBS tert-butyldimethylsilyl
- TIPS tri-iso-propylsilyl
- TES triethylsilyl
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
- R5 is H or F.
- the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
- TMS trimethylsilyl
- TDPS tert-butyldiphenylsilyl
- TDMS/TBS tert-butyldimethylsilyl
- TIPS tri-iso-propylsilyl
- TES triethylsilyl
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- R6 is phenyl
- R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
- R5 is H or F.
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- R6 is phenyl
- R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
- R5 is H or F.
- the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
- TMS trimethylsilyl
- TDPS tert-butyldiphenylsilyl
- TDMS/TBS tert-butyldimethylsilyl
- TIPS tri-iso-propylsilyl
- TES triethylsilyl
- the present invention provides a compound of general formula (VIII) or (IX):
- R2 is an acyl group, more preferably a benzoyl group or an acetyl group.
- R5 is H or F.
- the present invention provides a process for producing a compound of general formula (VI) or (VII) from a compound of general formula (VIII) or (IX) respectively, comprising the step of:
- R2 is an acyl group, more preferably a benzoyl group or an acetyl group.
- R5 is H or F.
- the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
- R6 is phenyl
- the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
- the present invention provides a process for separating a compound of general formula (II) from a compound of general formula (III) comprising the steps of:
- alkyl includes a straight chain or branched alkyl group and may be optionally substituted.
- straight chain or branched alkyl groups include but are not limited to methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, sec-butyl, tert-butyl, di- or tri-alkylated ethyl, propyl, butyl, pentyl or hexyl groups.
- Aryl includes mono-, bi- or polycyclic ring systems containing an aromatic residue and examples include phenyl, biphenyl and naphthyl. An aryl group may be optionally substituted.
- alkylaryl refers to any of mono-, bi- or polycyclic (including conjugated and fused) hydrocarbon ring systems preferably having 6 to 10 carbon atoms and containing an aromatic residue together with an alkyl linkage.
- Suitable alkylaryl groups include, but are not limited to, benzyl (i.e. —CH 2 phenyl).
- Acyl will be understood to mean a group containing the carboxyl C ⁇ O moiety though not being a carboxylic acid, ester or amide.
- Acyl groups include, but are not limited to, the acetyl group and benzoyl group.
- the synthesis of a 2-substituted 4-substituted 1,3-oxathiolane may be carried out by a number of methods to provide a mixture of the four stereoisomers, these being the two cis isomers and the two trans isomers, in proportions as shown in Table 1.
- a compound of general formula (II) or (III) is produced by reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III) as shown in Scheme 1:
- a compound of general formula (II) or (III) may also be produced by reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) as shown in Scheme 2 where R10 is a silyl protecting group.
- the 1,3-oxathiolane of general formula (V) is at least 60% ee of the (R) enantiomer, preferably at least 70%, more preferably greater than 85% ee, even more preferably greater than 95% ee and still more preferably greater than 99% ee.
- the skilled addressee will appreciate that the amount of compound (II) and compound (III) obtained from the reactions illustrated in Schemes 1 and 2 will depend on the %ee of the (R) enantiomer compound (V).
- the %ee of the (R) enantiomer of compound (V) is, for example, greater than 95%, then the (R,R) cis isomer of general formula (II) will be the major isomer formed.
- the %ee of the (R) enantiomer of compound (V) decreases the amount of compound (II) formed decreases and the amount of compound (III) increases accordingly.
- the trans isomers are also formed in the process.
- Particularly preferred general reaction conditions involves the coupling of N-benzoylcytosine (2) with 2-benzoyloxymethyl-1,3-oxathiolane-S-oxide (1) in the presence of trimethylsilyliodide (TMSI), triethylamine and catalytic amounts of copper(II)chloride in dichloromethane (Scheme 3).
- the reaction proceeds through initial activation of (1) undergoing a Sila-Pumerrer rearrangement.
- Copper(II)chloride is believed to play a role on inducing a ⁇ attack of silylated benzoyl cytosine, resulting in an increase in cis selectivity during the coupling.
- This increase in cis selectivity is modest and the amount of CuCl 2 can be reduced without a significant effect on the reaction.
- the Sila-Pummerrer rearrangement of (1) is conducted at ⁇ 50° C. and the coupling with the base to proceed at 0° C. overnight, before warming to room temperature and quenching.
- the quenched crude reaction mixture was filtered through celite which reduced the problem of solid formation which can complicate the workup process.
- the filtered reaction mixture was washed with dilute aqueous ammonia and dilute phosphoric acid.
- the resulting crude reaction mixture was purified by recrystallizing in methanol. Recrystallization in methanol gives the desired cis isomer almost exclusively. Recrystallization in methanol also enhances the optical purity and by using the technique of entrainment, optical purity can be improved further. This finding is particularly useful when starting with less optically pure starting material and is a particularly important finding of the present invention.
- the inventors have found that a correct choice of the groups R2, R3 and R4 is required for selective recrystallisation of an optically active compound of general formula (II) or (III) from the mixture.
- the choice of recrystallisation solvent is also dependent on the nature of the groups R2, R3 and R4.
- R4 acetyl or pivalyl or isobutyryl failed to selectively recrystallise the desired chirally pure compound.
- R3 or R4 of the compound of general formula II or III is benzoyl.
- R2 of the compound of general formula II or III is also benzoyl.
- the recrystallisation solvent of choice is therefore a C 1-6 alcohol or mixtures of C 1-6 alcohols.
- the C 1-6 alcohol may be a straight chain or branched chain alcohol.
- Methanol (MeOH), ethanol (EtOH), propanol and butanol are preferred and of these, methanol is particularly preferred.
- MeOH is particularly preferred to give the compound (II) in ee of greater than 99%.
- C 1-6 alcohols are also preferred recrystallisation solvents including mixtures of MeOH and another C 2-6 alcohol such as EtOH, propanol, butanol, pentanol and hexanol in a variety of ratios of MeOH:C 2-6 alcohol from about 2:98 to 98:2, about 5:95 to 95:5, about 10:90 to 90:10, about 20:80 to 80:20 or about 30:70 to 70:30.
- a preferred ratio of MeOH:C 2-6 alcohol is 90:10 and particularly preferred is a ratio of MeOH:C 2-6 alcohol 95:5. It is preferred that the C 1-6 alcohol or mixtures thereof contains no more than 5% water.
- Enhancement of optical purity is a desirable advantage of the present invention making possible the use of a starting material with a lower optical purity to yield a recrystallised product with higher optical purity, leading to a lower production cost.
- the selective recrystallisation step (b) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects is repeated at least once.
- the repetition of the selective recrystallisation step may facilitate an increase in the overall yield of the desired enantiomer as an additional amount of the desired enantiomer may be recovered as a result of the repeated step.
- the recrystallisation step may also be repeated to selectively recrystallise an isomer which was not obtained in the first selective recrystallisation step.
- the desired R,R-enantiomer may be selectively recrystallised in the first recrystallisation step and the S,S-enantiomer may be selectively recrystallised in the second recrystallisation step.
- the selective recrystallisation step (b) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects is an entrainment or a cyclic entrainment process.
- the inventors have surprisingly found that the yield of a preferred single enantiomer can be increased by entrainment.
- the addition of a small amount of the R,R-enantiomer favours the recrystallisation of the R,R-enantiomer.
- This seeding or entrainment process therefore advantageously increases the recrystallised yield of the desired enantiomer.
- the results obtained in Example 3 are shown in Table 6.
- the starting BOMO used in the coupling reaction can be of lower purity (i.e. R:S ratio) in view of the ability to increase the RR/SS ratio of the final coupled product using the recrystallisation method of the present invention.
- a racemic mixture of enantiomers can be resolved during the crystallization process.
- a mixture of enantiomers can crystallize either by the formation of a racemic compound or by the formation of a conglomerate.
- the crystals are in a lattice with a regular arrangement of both enantiomers in equal amounts.
- molecules of one enantiomer is preferentially attracted to the same enantiomer, thus crystallizes as a physical mixture of crystals belonging to one enantiomer or the other.
- R/S BOMO mixtures (at different ratios from 100:0 R/S to 50:50) were oxidized to the corresponding S-oxide with H 2 O 2 /HOAc, and then without crystallizing the resulting S-oxide this was coupled with benzoyl cytosine. It was hypothesized that if it was possible for the S-oxide itself to crystallize via conglomerate formation, then, a removed portion from this non-homogeneous mixture may yield a different optical bias than intended. The reaction was worked up the usual way, and the crude was recrystallized with and without entrainment.
- Table 11 shows the results of a study where crude (Starting R/S ratio: 97/3) was recrystallized with 14 volumes of methanol.
- Table 13 possibly shows that, at temperatures above 55° C. (or so), seeds partially dissolve. Thus temperatures below 55° C. are better. On the other hand at lower temperatures there is competing natural seeding, especially with high rates of seeding. This also could decrease the effectiveness of entrainment.
- the 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or general formula (III) produced or formed in step (a) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects is in the form of a conglomerate.
- the ability of these compounds to form conglomerates is surprising when taking into consideration that only 5% to 10% of racemates belong to the conglomerate forming group (Lorenz, H., et. al., Journal of the University of Chemical Technology and Metallurgy (2007) 42(1): 5-16).
- the desired enantiomer which is obtained by any one of the processes according to the first, second, third, fourth, sixth, seventh, eighth and tenth aspects of the invention does not comprise any detectable amount of an undesired isomer.
- the final step of the synthesis is the removal of the benzoyl protecting groups to obtain the debenzoylated product, for example compound (17) as shown in Scheme 5.
- Suitable deprotection methods include: catalytic NaOMe/MeOH, Methanolic Ammonia, and Aqueous Ammonia in Methanol.
- the sodium methoxide mediated hydrolysis was investigated first. This method deprotects quantitatively, however requires an aqueous workup to get rid of the salts non-chromatographically. Therefore as the final products, such as compound (17), may possess some water solubility, the workup reduces the yield.
- the methanolic ammonia method was also investigated. Methanolic ammonia again cleanly deprotected the molecule after overnight stirring, and after removal of the solvent, slurrying in acetone removed the more lipophilic by-products and yielded the product very cleanly. The reaction was equally successful whether the starting material were RR or SS (Table 14, experiments 2, 3, 4). Alternatively, it was found that aqueous ammonia in methanol could also be used. Deprotection using this method is slower but is clean however this involves the removal of water and thus is less convenient in larger scale than methanolic ammonia.
- novel 2-substituted 4-substituted 1,3-oxathiolane derivatives there is provided novel 2-substituted 4-substituted 1,3-oxathiolane derivatives.
- N-benzoyl derivatives of compounds of general formula VIII and IX are particularly preferred.
- HPLC analyses were done on a Waters 510 HPLC system, with a Chiralpak AD, 25 cm ⁇ 0.46 cm (ID) column, detecting at 254 nm.
- the solvent system was 20% MeOH in acetonitrile, running isochratically, at a flow rate of 2 mL/min.
- the comparative data provided in the following table shows that entrainment results in an increased yield of the RR enantiomer.
- Each sample came from a reaction where the starting ratio for the BOMO was 97(R)/3(S) (The R/S ratio of the crude was not done for these samples).
- the crude was recrystallized by dissolving while refluxing in 14 volumes of methanol. For entrainment 14 mg seeds (pure R,R) per gram of crude were used. Seeding was done at a temperature between 55° C. and 56° C. After the specified time, the crystals were filtered, washed with methanol, dried, and analyzed with HPLC. The results are shown in the following table.
- the resulting light yellow solution was stirred for 60 minutes while maintaining the temperature between ⁇ 40° C. and ⁇ 50° C.
- copper(II)chloride 1.3 g, 0.010 mol
- N-benzoyl-5-fluorocytosine 9.3 g, 0.040 mol
- the resulting mixture was stirred at ⁇ 50° C. for 15 minutes and then was allowed to warm to 0° C. over 1 hour.
- the reaction mixture was stirred at this temperature overnight. After overnight stirring, the reaction was stirred at room temperature for 1 hour, cooled again in ice, quenched with the addition of saturated sodium bicarbonate (75 mL).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivatives thereof. The present invention also relates to novel 2-substituted 4-substituted 1,3-oxathiolanes derivatives.
Description
This application is a 35 U.S.C. §371 national stage filing of International Application No. PCT/AU2008/001433, filed Sep. 26, 2008, which is related and claims priority to U.S. Provisional Application Ser. No. 60/981,252, filed Oct. 19, 2007, and Australian Patent Application No. 2007905335, filed Sep. 28, 2007. The entire contents of each of these applications are explicitly incorporated herein by this reference.
The present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivatives thereof of general formula (I):
The present invention also relates to novel 2-substituted 4-substituted 1,3-oxathiolanes derivatives.
Classes of compounds known as 2-substituted 4-substituted 1,3-oxathiolanes, in particular derivatives of analogues of pyrimidine nucleosides have been found to have potent antiviral activity. In particular, these compounds have been found to act as potent inhibitors of HIV-1 replication in T-lymphocytes over a prolonged period of time with less cytotoxic side effects than compounds known in the art (see for example Belleau et. al. (1993) Bioorg. Med. Chem. Lett. Vol. 3, No. 8, 1723-1728). These compounds have also been found active against 3TC-resistant HIV strains (see for example Taylor et. al. (2000) Antiviral Chem. Chemother. Vol. 11, No. 4, 291-301; and Stoddart et. al. (2000) Antimicrob. Agenst Chemother. Vol. 44, No. 3, 783-786). These compounds are also useful in prophylaxis and treatment of hepatitis B virus infections. These compounds may be produced in accordance with the methods disclosed in WO 92/08717, WO 95/29176, WO 02/102796 and WO 2006/096954.
Compounds of the 2-substituted 4-substituted 1,3-oxathiolane family contain two chiral centres. Compounds that contain two chiral centres can exist as a mixture of four stereoisomers, where the configuration at the two chiral centres is (R,R) or (R,S) or (S,R) or (S,S). The (R,R) and (S,S) forms are known as cis enantiomers as they are non-superimposible mirror images of each other and the (R,S) and (S,R) forms are known as the trans enantiomers for the same reason. For human therapeutic use it is usually typically required to isolate the compound in only one of the stereoisomeric forms, also known as a chirally pure form. It can be that synthesis of a single stereoisomer can be achieved from a starting material with a single chiral centre in enantiomerically pure form or a suitable intermediate.
For example, cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane may be produced by the methods described by Mansour et al., “Anti-Human Immunodeficiency Virus and Anti-Hepatitis-B Virus Activities and Toxicities of the Enantiomers of 2′-Deoxy-3′-oxa-4′-thiacytidine and Their 5-Fluoro Analogues in vitro”, J. Med. Chem., (1995), Vol. 38, No. 1, 1-4, as well as the methods disclosed in U.S. Pat. No. 6,228,860, Nucleosides and Nucleotides, (1995) 14(3-5) 627-735 and Caputo et. al. in Eur. j. Org. Chem. (1999) Vol. 6, 1455-1458.
However methods of synthesis do not always form the new chiral centres stereospecifically, but instead give a ratio know as the enantiomeric excess (ee):
When compounds are desired as a single form, for example, if only the two (R, R) and (S, S)cis enantiomers are present, a single form being either the (R, R) or the (S, S) form, may be obtained by resolution of the mixture of the two cis enantiomers by chiral HPLC. A review of this technology may be found in “Enantiomers, Racemates and Resolutions” by J. Jacques, A. Collet & S. H. Wilen (John Wiley & Sons, 1981).
Alternatively, compounds or any convenient intermediate may be resolved by enzyme mediated enantioselective catabolism with a suitable enzyme such as cytidine deaminase or selective enzymatic degradation of a suitable derivative (see for example Storer et. al., “The resolution and Absolute Stereochemistry of the Enantiomers of cis 1[2(Hydroxomethyl)-1,3-Oxathiolan-5-Yl)Cytosine (BCH-189): Equipotent Anti-HIV Agents”, Nucleosides & Nucleotides, (1993) 12(2), 225-236).
The reaction of a racemic mixture of a compound with an optically active resolving acid or base can also be used for the enantiomeric resolution of the compound. For example, WO 2006/096954 discloses a method for the preparation of optically active cis 1,3-oxathiolanes. The method involves, (a) reacting a 1,3-oxathiolane compound in the cis configuration with a chiral acid to produce two diastereomeric salts; (b) recovering one of the two diastereomeric salts; and (c) desalting to remove the chiral acid. Preferred chiral acids include (+)-L-tartaric acid, (1R)-(−)-10-camphorsulfonic acid, (−)-2,3-dibenzoyl-tartaric acid or (−)-L-malic acid. The method also discloses the addition of an achiral acid together with the chiral acid to produce the two diastereomeric salts. A disadvantage with the method of WO 2006/096954 however, is the salt formation step. This step requires the use of chiral acid reagents and in some cases also achiral acids. The salt formation step also requires the introduction of a further desalting step to obtain the desired optically active cis product.
The use of additional reagents, such as chiral acids, and extra steps in a process, such as the desalting step required in the method of WO 2006/096954, are undesirable in a commercial setting as they add to production costs as well as increase the production time of the desired product. Furthermore, with each additional step in a process, there is the potential for inefficient recovery of the final end product due to losses occurring with each step of the process.
The present inventors have found that by the correct choice of groups R2, R3 and R4, an optically active compound of general formula (II) or (III) may be obtained by selective recrystallisation. The present inventors have also found that the recrystallisation solvent of choice is selected on the basis of groups R2, R3 and R4. The present invention avoids the salting and desalting steps required by previous methods and provides a simpler, more efficient process to produce optically active cis 1,3-oxathiolanes. In a particularly preferred aspect the invention provides a way of separating an undesired diastereomer such as the trans diastereomer and enhancing the optical purity of the cis isomer by recrystallisation. The present invention also provides novel 2-substituted 4-substituted 1,3-oxathiolane derivatives.
According to a first aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
- In a particularly preferred embodiment, R6 is phenyl.
-
According to a second aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
- In a particularly preferred embodiment, R6 is phenyl.
-
According to a third aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein
- R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
-
-
- In a particularly preferred embodiment, R6 is phenyl.
-
According to a fourth aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)O—C1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
-
- In a particularly preferred embodiment, R6 is phenyl.
In a fifth aspect, the present invention provides a compound of general formula (VIII) or (IX):
wherein
-
- R2 is H, C(O)C1-6alkyl, C(O)O—C1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
- R5 is H, Br, Cl, F, I or CF3.
In a sixth aspect, the present invention provides a process for producing a compound of general formula (VI) or (VII) from a compound of general formula (VIII) or (IX) respectively, comprising the step of:
-
- (a) deprotecting a compound of general formula (VIII) or (IX) to produce a compound of general formula (VI) or (VII) respectively:
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
- R5 is H, Br, Cl, F, I or CF3.
-
In accordance with a seventh aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl;
- R5 is H, Br, Cl, F, I or CF3; and
- R10 is a silyl protecting group of general formula SiR7R8R9 as previously defined; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
- In a particularly preferred embodiment, R6 is phenyl.
-
In accordance with an eighth aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)O—C1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- R10 is a silyl protecting group of general formula SiR7R8R9 as previously defined; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
-
- In a particularly preferred embodiment, R6 is phenyl.
In accordance with a ninth aspect the present invention provides a compound of formula (XIII) and diastereomers thereof:
In accordance with a tenth aspect the present invention provides a process for separating a compound of general formula (II) from a compound of general formula (III) comprising the steps of:
-
- (a) providing a mixture of 2-substituted 4-substituted 1,3-oxathiolanes of general formula (II) and (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- (b) separating the compound of general formula (II) from the compound of general formula (III) by selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6 alcohols.
- In a particularly preferred embodiment, R6 is phenyl.
-
The present invention will now be described without limitation by reference to the preferred embodiments.
The present invention advantageously provides a process for obtaining an optically active compound of general formula II or III by selective recrystallisation.
The compounds of general formula (II) or (III) may be selectively recrystallised from a mixture of the two cis isomers or a mixture of the four stereoisomers, these being the two cis isomers (II) and (III) and the two trans isomers (XI) and (XII) as follows:
Cis Isomers:
Trans Isomers:
According to a first aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
-
In a particularly preferred embodiment, R6 is phenyl.
Preferably R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
Preferably R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
Preferably R5 is H or F.
Preferably the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
According to a second aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein
- R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
-
In a particularly preferred embodiment, R6 is phenyl.
Preferably R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
Preferably R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
Preferably R5 is H or F.
Preferably the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
According to a third aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
In a particularly preferred embodiment, R6 is phenyl.
Preferably R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
Preferably R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
Preferably R5 is H or F.
Preferably the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
According to a fourth aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
In a particularly preferred embodiment, R6 is phenyl.
Preferably R2 is an acyl group, even more preferably a benzoyl group or an acetyl group.
Preferably R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H.
Preferably R5 is H or F.
Preferably the silyl group of general formula SiR7R8R9 is selected from the group consisting of trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS/TBS), tri-iso-propylsilyl (TIPS) and triethylsilyl (TES).
In a fifth aspect, the present invention provides a compound of general formula (VIII) or (IX):
wherein
-
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
- R5 is H, Br, Cl, F, I or CF3.
Preferably R2 is an acyl group, more preferably a benzoyl group or an acetyl group.
Preferably R5 is H or F.
In a sixth aspect, the present invention provides a process for producing a compound of general formula (VI) or (VII) from a compound of general formula (VIII) or (IX) respectively, comprising the step of:
-
- (a) deprotecting a compound of general formula (VIII) or (IX) to produce a compound of general formula (VI) or (VII) respectively:
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
- R5 is H, Br, Cl, F, I or CF3.
-
Preferably R2 is an acyl group, more preferably a benzoyl group or an acetyl group.
Preferably R5 is H or F.
In accordance with a seventh aspect, the present invention provides a process for producing a compound of general formula (II) comprising the steps of:
-
- (a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl;
- R5 is H, Br, Cl, F, I or CF3; and
- R10 is a silyl protecting group of general formula SiR7R8R9 as previously defined; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee; and
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
-
In a particularly preferred embodiment, R6 is phenyl.
In accordance with an eighth aspect, the present invention provides a process for producing a compound of general formula (VI) comprising the steps of:
-
- (a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- R10 is a silyl protecting group of general formula SiR7R8R9 as previously defined; and
- wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee;
- (b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
- (c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
-
-
- In a particularly preferred embodiment, R6 is phenyl.
In accordance with a ninth aspect the present invention provides a compound of formula (XIII) and diastereomers thereof:
In accordance with a tenth aspect the present invention provides a process for separating a compound of general formula (II) from a compound of general formula (III) comprising the steps of:
-
- (a) providing a mixture of 2-substituted 4-substituted 1,3-oxathiolanes of general formula (II) and (III):
-
-
- wherein
- R2 is H, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)C6-12aryl, C(O)OC6-12aryl, C(O)C6-12arylalkyl, C(O)OC6-12arylalkyl, C(O)C1-6alkylaryl, C(O)OC1-6 alkylaryl, or a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6 alkylaryl;
- R3 and R4 are the same or different and are each individually selected from H or C(O)—R6;
- R6 is C6-12aryl or C1-6alkylaryl in which the C1-6alkylaryl is preferably C1-6alkylC6-12aryl; and
- R5 is H, Br, Cl, F, I or CF3; and
- (b) separating the compound of general formula (II) from the compound of general formula (III) by selective recrystallisation of the compound of general formula
- (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6 alcohols.
- In a particularly preferred embodiment, R6 is phenyl.
-
Definitions
It will be understood by those skilled in the art that the term “alkyl” includes a straight chain or branched alkyl group and may be optionally substituted. Examples of straight chain or branched alkyl groups include but are not limited to methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, sec-butyl, tert-butyl, di- or tri-alkylated ethyl, propyl, butyl, pentyl or hexyl groups.
“Aryl” includes mono-, bi- or polycyclic ring systems containing an aromatic residue and examples include phenyl, biphenyl and naphthyl. An aryl group may be optionally substituted.
As used herein, the term “alkylaryl” refers to any of mono-, bi- or polycyclic (including conjugated and fused) hydrocarbon ring systems preferably having 6 to 10 carbon atoms and containing an aromatic residue together with an alkyl linkage. Suitable alkylaryl groups include, but are not limited to, benzyl (i.e. —CH2phenyl).
“Acyl” will be understood to mean a group containing the carboxyl C═O moiety though not being a carboxylic acid, ester or amide. Acyl groups include, but are not limited to, the acetyl group and benzoyl group.
“Silyl protecting groups” will be familiar to the skilled addressee as provided for example in Greene, T. W. and Wuts, P. G. M “Protective groups in organic synthesis” (3rd Edition) 1999 John Wiley & Sons Inc.
The synthesis of a 2-substituted 4-substituted 1,3-oxathiolane may be carried out by a number of methods to provide a mixture of the four stereoisomers, these being the two cis isomers and the two trans isomers, in proportions as shown in Table 1.
| TABLE 1 | |||||
| Mass | Purity | cis:trans | |||
| Experiment | Scale | recovery | (NMR) | ratio | cis yield |
| 1 | 5 g | 89% | 69% | 2.8:1 | 45% |
| 2 | 5 g | 89% | 70% | 2.5:1 | 45% |
| 3 | 10 g | 86% | 62% | 2.9:1 | 40% |
| 4 | 10 g | 84% | 67% | 2.6:1 | 41% |
In accordance with the present invention, a compound of general formula (II) or (III) is produced by reacting a base of general formula (IV) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) or (III) as shown in Scheme 1:
A compound of general formula (II) or (III) may also be produced by reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) as shown in Scheme 2 where R10 is a silyl protecting group.
The 1,3-oxathiolane of general formula (V) is at least 60% ee of the (R) enantiomer, preferably at least 70%, more preferably greater than 85% ee, even more preferably greater than 95% ee and still more preferably greater than 99% ee. The skilled addressee will appreciate that the amount of compound (II) and compound (III) obtained from the reactions illustrated in Schemes 1 and 2 will depend on the %ee of the (R) enantiomer compound (V). When the %ee of the (R) enantiomer of compound (V) is, for example, greater than 95%, then the (R,R) cis isomer of general formula (II) will be the major isomer formed. As the %ee of the (R) enantiomer of compound (V) decreases the amount of compound (II) formed decreases and the amount of compound (III) increases accordingly. The trans isomers are also formed in the process.
Particularly preferred general reaction conditions according to an embodiment of the invention involves the coupling of N-benzoylcytosine (2) with 2-benzoyloxymethyl-1,3-oxathiolane-S-oxide (1) in the presence of trimethylsilyliodide (TMSI), triethylamine and catalytic amounts of copper(II)chloride in dichloromethane (Scheme 3).
The reaction proceeds through initial activation of (1) undergoing a Sila-Pumerrer rearrangement. Copper(II)chloride is believed to play a role on inducing a β attack of silylated benzoyl cytosine, resulting in an increase in cis selectivity during the coupling. However this increase in cis selectivity is modest and the amount of CuCl2 can be reduced without a significant effect on the reaction. The Sila-Pummerrer rearrangement of (1) is conducted at −50° C. and the coupling with the base to proceed at 0° C. overnight, before warming to room temperature and quenching.
The quenched crude reaction mixture was filtered through celite which reduced the problem of solid formation which can complicate the workup process. The filtered reaction mixture was washed with dilute aqueous ammonia and dilute phosphoric acid. The resulting crude reaction mixture was purified by recrystallizing in methanol. Recrystallization in methanol gives the desired cis isomer almost exclusively. Recrystallization in methanol also enhances the optical purity and by using the technique of entrainment, optical purity can be improved further. This finding is particularly useful when starting with less optically pure starting material and is a particularly important finding of the present invention.
Selective Recrystallisation
The inventors have found that a correct choice of the groups R2, R3 and R4 is required for selective recrystallisation of an optically active compound of general formula (II) or (III) from the mixture. The choice of recrystallisation solvent is also dependent on the nature of the groups R2, R3 and R4.
Cytosine protected with acetyl, isobutyrylcarbonyl, pivalylcarbonyl, cyclohexylcarbonyl, p-toluoyl and benzoyl groups was coupled with BOMO-sulfoxide as shown in Scheme 4.
For example, when R2 is benzoyl, R5=H, R3=H and R4=Acetyl, recrystallisation from a mixture of cis isomers (R,R and S,S) (compounds II and III) and trans isomers (R,S and S,R) (compounds XI and XII) does not give any separation as shown in Table 2. It was found that the benzoyl protected cytosine coupled product crystallizes efficiently with high cis selectivity.
| TABLE 2 | |||||
| Exper- | NMR | cis:trans | |||
| iment | R4 | purity | ratio | cis yield | Recrystallisation |
| Summary | benzoyl | 62-70% | 2.5-2.8:1 | 40-45% | Recrystallisation |
| expt1-4 | gave II in >99:1 | ||||
| ratio | |||||
| 5 | acetyl | 66% | 2.26:1 | 46% | Recrystallisation |
| did not give II | |||||
| 6 | isobutyryl | 64% | 2.74:1 | 47% | No |
| recrystallisation | |||||
| from MeOH | |||||
| 7 | pivalyl | 64% | 2.79:1 | 47% | No |
| recrystallisation | |||||
| from MeOH | |||||
By correct choice of the groups R2, R3 and R4 conditions can be selected that lead to the selective resolution of a compound of, for example, formula (II) by recrystallisation from a mixture of all four stereoisomers. As shown in Table 2, where R2=benzoyl and R3=H, and if R4 is varied as follows then R4=benzoyl was found to give the recrystallisation to chirally pure compound, while R4=acetyl or pivalyl or isobutyryl failed to selectively recrystallise the desired chirally pure compound.
Accordingly, in a preferred embodiment of the process according to the first, second, third, fourth, sixth, seventh, eighth and tenth aspects of the present invention, R3 or R4 of the compound of general formula II or III is benzoyl. In a preferred embodiment, R2 of the compound of general formula II or III is also benzoyl.
Cis Selective Recrystallisation
One of the most attractive advantages of the N-benzoyl route is that the recrystallisations in methanol almost exclusively yield the desired cis(R,R) isomer. Preferred embodiments of the present invention show that at 5 g and 10 g scale reactions when using 0.2 equivalents of CuCl2, the reactions were cis selective with selectivity between 2.86:1 (74%) to 2.5:1 (71%). Recrystallizing in 14-15× volumes of methanol (as compared to the mass of the crude) gave almost exclusively the cis isomer.
Recrystallisation Solvents
The recrystallisation solvent of choice is therefore a C1-6alcohol or mixtures of C1-6 alcohols. The C1-6alcohol may be a straight chain or branched chain alcohol. Methanol (MeOH), ethanol (EtOH), propanol and butanol are preferred and of these, methanol is particularly preferred. As shown in Tables 3 and 4, MeOH is particularly preferred to give the compound (II) in ee of greater than 99%.
| TABLE 3 | ||||
| Recrystallisation | cis:trans | |||
| Experiment | method | ratio | cis yield | cis recovery, |
| 1 | x15 volumes MeOH | >99:1 | 4.1 g | 87% |
| 2 | x15 volumes MeOH | >99:1 | 4.0 g | 85% |
| 3 | x14.5 volumes MeOH | >99:1 | 7.2 g | 88% |
| 4 | x11 volumes MeOH | >98:2 | 4.6 g | 93% |
| TABLE 4 | |||||
| C/T Ratio | |||||
| (After | |||||
| Mass | NMR | C/T | Recrystallization | Recrys- | cis |
| Recovery | Purity | Ratio | Method | tallization) | Yield |
| 84-89% | 62-70% | 2.5-2.9:1 | Refluxing | >98-99:1 | 35-39% |
| Methanol | |||||
| (×10-15 vol) | |||||
Mixed Solvent Systems
Recrystallizations with entrainment in mixed solvent systems was examined. Mixtures of C1-6alcohols are also preferred recrystallisation solvents including mixtures of MeOH and another C2-6alcohol such as EtOH, propanol, butanol, pentanol and hexanol in a variety of ratios of MeOH:C2-6alcohol from about 2:98 to 98:2, about 5:95 to 95:5, about 10:90 to 90:10, about 20:80 to 80:20 or about 30:70 to 70:30. A preferred ratio of MeOH:C2-6 alcohol is 90:10 and particularly preferred is a ratio of MeOH:C2-6alcohol 95:5. It is preferred that the C1-6alcohol or mixtures thereof contains no more than 5% water.
All recrystallizations were seeded at 53° C., 14 mg of seed/g crude, stirred at 1000 rpm, with ×14 volumes of solvent. Recrystallizations were done on a crude mixture coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). The results are shown in Table 5. However, in contrast to the recrystallization results shown in Tables 10 and 11 below, HPLC analysis of crude gave an approximate crude R/S ratio of 86/14. However when R/S ratio decreases, specially below 90:10, there is a propensity for trans isomer to also crystallize (Table 9 below). In this set of experiments, the trans isomer was observed uniformly about 10-12%. Therefore the observed RR/SS ratio was corrected for the presence of RR and SS trans isomers. Regardless, there was a substantial improvement in optical activity. 100% methanol is particularly preferred as shown in Table 5. Mixtures of methanol, for example with 5% 1-propanol or 5% 1-butanol, are also particularly preferred.
| TABLE 5 | ||||
| Corrected | ||||
| C/T | Observed | Optical | ||
| Expt | Recrystallization Solvent | Ratio | Purity | Purity |
| # | System | (NMR) | S,S | R,R | SS | RR |
| 1 | Methanol 100% | 88/12 | 2.33 | 97.67 | 2.65 | 97.35 |
| 2 | Methanol 95%, Ethanol 5% | 88/12 | 2.68 | 97.32 | 3.06 | 96.94 |
| 3 | Methanol 95%, 1-Propanol | 89/11 | 2.26 | 97.74 | 2.53 | 97.47 |
| 5% | ||||||
| 4 | Methanol 95%, 2-Propanol | 89/11 | 2.97 | 97.03 | 3.33 | 96.67 |
| 5% | ||||||
| 5 | Methanol 95%, 1- | 88/12 | 2.52 | 97.48 | 2.82 | 97.18 |
| Butanol 5% | ||||||
| 6 | Methanol 95%, 1-Pentanol | 88/12 | 2.95 | 97.05 | 3.36 | 96.64 |
| 5% | ||||||
| 7 | Methanol 95%, 1-Hexanol | 88/12 | 2.57 | 97.43 | 3.93 | 96.07 |
| 5% | ||||||
| 8 | Methanol 99%, Water 1% | 90/10 | 2.98 | 97.02 | 3.21 | 96.79 |
| 9 | Methanol 95%, Water 5% | 87/13 | 4.6 | 95.4 | 5.24 | 94.76 |
| Note: | ||||||
| This set of recrystallizations was done on a crude mixture coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). | ||||||
Enhancement of Optical Purity
Enhancement of optical purity is a desirable advantage of the present invention making possible the use of a starting material with a lower optical purity to yield a recrystallised product with higher optical purity, leading to a lower production cost.
Repetition of Recrystallisation Step and Entrainment
In a preferred embodiment of the invention, the selective recrystallisation step (b) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects is repeated at least once. The repetition of the selective recrystallisation step may facilitate an increase in the overall yield of the desired enantiomer as an additional amount of the desired enantiomer may be recovered as a result of the repeated step. It will be understood however that the the recrystallisation step may also be repeated to selectively recrystallise an isomer which was not obtained in the first selective recrystallisation step. Thus, for example, the desired R,R-enantiomer may be selectively recrystallised in the first recrystallisation step and the S,S-enantiomer may be selectively recrystallised in the second recrystallisation step.
In a particularly preferred embodiment, the selective recrystallisation step (b) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects is an entrainment or a cyclic entrainment process. The inventors have surprisingly found that the yield of a preferred single enantiomer can be increased by entrainment. As demonstrated by the results obtained in Example 3 of the Experimental Section the addition of a small amount of the R,R-enantiomer favours the recrystallisation of the R,R-enantiomer. This seeding or entrainment process therefore advantageously increases the recrystallised yield of the desired enantiomer. The results obtained in Example 3 are shown in Table 6.
| TABLE 6 | |||
| Actual Enantiomer | |||
| Ratio R/S | |||
| (calculated based | Recrystallization Method | ||
| on purities | RR/SS ratio without | RR/SS ratio with | |
| Expt | of starting BOMOs) | Entrainment | Entrainment |
| 1 | 98.3/1.7 | 99.0-99.4/1.0-0.6 | 99.5-99.8/0.5-0.2 |
| 2 | 94.2/5.8 | 98.14/1.86 | 99.33/0.67 |
| 3 | 90.0/10.0 | 97.67/2.33 | 99.23/0.77 |
| 4 | 81.7/18.3 | 95.1/4.9 | 98.2/1.8 |
In order to examine the optical purity enhancement during the recrystallization, starting 2-benzoyloxymethyl-1,3-oxathiolane-S-oxide (BOMO) (R-BOMO (11) and S-BOMO (18)) samples were analysed by chiral HPLC.
As can be seen from Table 7, supplied BOMOs were of varied purity.
| TABLE 7 | |||||
| BOMO | Actual | ||||
| Sample | S % (HPLC) | R % (HPLC) | R/S Ratio | ||
| R-1 | 1.72 | 97.60 | 98.3/1.7 | ||
| S-1 | 84.71 | 11.62 | 12.1/87.9 | ||
| S-2 | 80.80 | 15.01 | 15.7/84.3 | ||
| R-3 | 2.51 | 95.33 | 97.4/2.6 | ||
| R-4 | 2.67 | 96.26 | 97.3/2.7 | ||
| Note that the samples often contained other impurities as well, which is the reason for differing R/S ratios as compared to HPLC analysis. | |||||
Optical Purity Enhancement Via Two Recrystallisation
The results from doing two recrystallizations in order to obtain very pure product are shown in Table 8. These recrystallizations were done without entrainment. Interestingly the solubility of the pure product appeared to be lower in methanol as compared to the crude product. This may be because that impurities present could be helping to solubilize the product. For example the crude product could be recrystallized in refluxing (10-15×) methanol readily. However with pure product we found that it was not easy to dissolve product even in ×25 volumes of refluxing methanol, generally we used ×40 volumes of refluxing methanol (in the example below we used ×30 volumes), but still with high recovery.
‘Pure’ R BOMO (R/S ratio 98.3/1.7) was used in the experiment. The first recrystallization in ×15 volumes of methanol yielded a product with a RR/SS ratio of 99.13/0.87. The 2nd recrystallization (in ×30 volumes of methanol) increased the RR/SS ratio to 99.6/0.4 with a recovery of 95%. Because the recovery from the second recrystallization is high a second recrystallization could also be attractive when there is some trans isomer left from the first recrystallization.
| TABLE 8 | |||
| 1st | 2nd | ||
| Starting | Recrystallization | recrystallization | Recovery in the |
| R/S | RR | RR | 2nd | ||
| ratio | isomer | SS isomer | isomer | SS isomer | recrystallization |
| 98.3/1.7 | 99.13 | 0.87 | 99.60 | 0.4 | 95% |
Therefore, the starting BOMO used in the coupling reaction can be of lower purity (i.e. R:S ratio) in view of the ability to increase the RR/SS ratio of the final coupled product using the recrystallisation method of the present invention.
Optical Purity Enhancement Via Entrainment
A racemic mixture of enantiomers can be resolved during the crystallization process. A mixture of enantiomers can crystallize either by the formation of a racemic compound or by the formation of a conglomerate. In a racemic compound, the crystals are in a lattice with a regular arrangement of both enantiomers in equal amounts. However in a conglomerate, molecules of one enantiomer is preferentially attracted to the same enantiomer, thus crystallizes as a physical mixture of crystals belonging to one enantiomer or the other. If the material of interest crystallizes as a conglomerate, then a process known as entrainment (essentially by using the pure crystals as seeds for crystallization of the enantiomer of interest) could be used to preferentially crystallize the desired enantiomer, enhancing the optical purity.
Entrainment could be affected by many variables:
-
- Temperature at which the seeding is conducted: If the temperature is too low, natural crystallization may have started. If the temperature is too high some of the seed crystals added would dissolve;
- The amount of seed crystals used;
- Purity and the particle size of the seeds;
- Rate of stirring during the crystallization;
- Time length of stirring;
- Volume of the solvent—methanol;
- Quality of the crude also could play a role. For example we have found that the pure product is less soluble in methanol than in the presence of impurities.
Optical Purity Enhancement During Recrystallization when the Starting BOMO is an R/S Mixture
R/S BOMO mixtures (at different ratios from 100:0 R/S to 50:50) were oxidized to the corresponding S-oxide with H2O2/HOAc, and then without crystallizing the resulting S-oxide this was coupled with benzoyl cytosine. It was hypothesized that if it was possible for the S-oxide itself to crystallize via conglomerate formation, then, a removed portion from this non-homogeneous mixture may yield a different optical bias than intended. The reaction was worked up the usual way, and the crude was recrystallized with and without entrainment.
First all solvent was removed from the crude material. This was then refluxed in 14 volumes of methanol till all the material was in solution. Next this was allowed to cool with stirring while monitoring the temperature. At the temperature of approximately 55° C., the stirred mixture was seeded with Pure ‘R,R’ isomer, allowed to come to room temperature and stirred overnight. The crystallized mixture was then filtered, washed with methanol and analyzed via chiral HPLC. As a control an identical sample was refluxed in methanol till all were in solution, and then allowed to cool without any stirring or seeding.
In summary, the results in Table 9 below show that there is a substantial optical purity enhancement during the crystallization, even without entrainment. Even with a starting BOMO R/S ratio of 80/20, the RR/SS ratio, even without entrainment has increased to 95/5. However with entrainment, the enhancement is even higher. Starting BOMO R/S ratio of as low as 90/10 gave a final purity over 99%, while an R/S ratio of 80/20 gave a purity over 98%. This information shows that starting BOMO need not be highly pure to get a high product purity. However it is also interesting to note that as the optical purity of the starting material goes down, the quality of the cis-trans separation also decreases. Generally below R/S ratio of 90/10, trace presence of the trans isomer could be seen (see entries 4 and 5, Table 9). However a second recrystallization should remove this trans isomer as previously discussed.
| TABLE 9 | |||||
| Actual | |||||
| R/S | RR/SS | ||||
| Intended | Ratio | Ratio | |||
| BOMO | (calc. | of the | |||
| R/S | based on | Crude | Recrystallization Method | ||
| ratio | purities | Coupled | Presence of | RR/SS | ||
| (by | of | Product | Trans after | ratio | RR/SS | |
| manual | starting | (HPLC | recrystallization | without | ratio with | |
| Expt # | mixing) | BOMOs) | analysis) | (NMR estimation) | Entrainment | Entrainment |
| 1 | 100/0 | 98.3/1.7 | — | No Trans | 99.0-99.4/ | 99.5-99.8/ |
| present | 1.0-0.6 | 0.5-0.2 | ||||
| 2 | 95/5 | 94.2/5.8 | 96/4 | <1% | 98.14/1.86 | 99.33/0.67 |
| 3 | 90/10 | 90/10 | 94.2/5.8 | <1% | 97.67/2.33 | 99.23/0.77 |
| 4 | 80/20 | 81.7/18.3 | 89.5/10.5 | 2-4% | 95.1/4.9 | 98.2/1.8 |
| 5 | 50/50 | 57/43 | 67/33 | 20% | — |
| NOTE: | |||||
| When the presence of trans is less than 4-5%, NMR estimation is not accurate due to noise etc., under standard NMR acquisition conditions. | |||||
Optical Purity Enhancement During Recrystallization of ‘S’ BOMO Reactions
With a true conglomerate, entrainment induced optical purity enhancement could occur with either enantiomers. To test this, an analogous reaction with a sulfoxide derived from S enriched BOMO (R/S ratio 12/88) was conducted. The crude reaction mixture derived from the coupling of S-BOMO sulfoxide with benzoyl cytosine was recrystallized with and without entrainment. Indeed the results shown in Table 10 with entrainment were similar to the analogous experiment where R/S ratio was 90/10.
| TABLE 10 | |||||
| Recrystallization | Starting Purity | ||||
| Method | (R/S ratio) | % R,R | % S,S | ||
| Entrainment | 12.1/87.9 | 1.5 | 98.5 | ||
| No Entrainment | 12.1/87.9 | 2.2 | 97.8 | ||
Examination of the Variables Affecting Entrainment
Time
Generally a time effect on the optical purity was observed. Standing overnight was found to be optimum and convenient. At 1.5 hours or 3 hours intervals it appeared the crystallization was not complete and thus generally overnight standing was used (Tables 12 and 13). Keeping more than 1 day, while improved the purity, did not improve the purity significantly more.
Table 11 shows the results of a study where crude (Starting R/S ratio: 97/3) was recrystallized with 14 volumes of methanol.
| TABLE 11 | ||
| Optical Purity | ||
| Time allowed | Recrystallization | Recrystallization | |
| for | with seeding | without seeding | |
| Experiment | crystallization | (14 mg/g crude) | or stirring |
| 1 | 1.5 hrs | 99.3/0.7 | 98.4/1.6 |
| 2 | 3 hrs | 98.4/1.6 | 98.4/1.6 |
| 3 | 4 days | 98.6/1.4 | 99.5/0.5 |
Stirring and Seeding
To test the effects of the variables, seeding and stirring, the following experiments were done. Even though the reaction was done using 80:20, R/S mixture of BOMO (actual R/S ratio: 82:18), for these experiments the crude itself was analyzed separately via HPLC.
For these experiments, all solvent is removed from the crude material first. This is then refluxed in 14 volumes of methanol until all material is in solution. Next this is allowed to cool with stirring (at the specified rate) or without stirring, while monitoring the temperature. At the temperature of 55° C., the stirred mixture is seeded with Pure ‘R,R’ cis isomer or not seeded and stirred overnight while allowing the temperature to come to room temperature. The crystallized mixture is then filtered, washed with methanol and analyzed via HPLC. The results are shown in Table 12. These results show that stirring is always better than no stirring. It may be that stirring could generate seeds and distribute them all over, stirring without adding seeds give higher optical purity products than recrystallizations where seeds had been added, but no stirring is done. Crystallization is essentially complete by 1 day, but purity improves slightly with time (Table 11).
| TABLE 12 | ||
| CONDITIONS | ||
| Seeds |
| Amounts of | ||||||
| Standing | Rate of | Seeds | Temperature | |||
| time | Stirring | Seeded | (mg of seeds/g | of seeding | RESULTS |
| Expt # | (days) | (rpm) | (Yes/No) | crude) | ° C. | S,S | R,R |
| 1 | 1 | 1000 | Y | 14 | 55 | 0.83 | 99.17 |
| 2 | 1 | 0 | Y | 14 | 55 | 1.71 | 98.29 |
| 3 | 1 | 1000 | N | — | — | 1.45 | 98.55 |
| 4 | 1 | 0 | N | — | — | 1.81 | 98.19 |
| 5 | 3 | 1000 | Y | 14 | 55 | 0.68 | 99.32 |
| Note: | |||||||
| This set of recrystallization was done on a crude mixture coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). However HPLC analysis of crude gave an approximate R/S ratio of 95.3/4.7. | |||||||
Temperature
The results obtained in Table 13 possibly shows that, at temperatures above 55° C. (or so), seeds partially dissolve. Thus temperatures below 55° C. are better. On the other hand at lower temperatures there is competing natural seeding, especially with high rates of seeding. This also could decrease the effectiveness of entrainment.
| TABLE 13 | ||
| CONDITIONS | ||
| Seeds |
| Amounts of | ||||||
| Standing | Rate of | Seeds | Temperature | |||
| time | Stirring | Seeded | (mg of seeds/g | of seeding | RESULTS |
| Expt # | (days) | (rpm) | (Yes/No) | crude) | ° C. | S,S | R,R |
| 1 | 1 | 1000 | Y | 14 | 55 | 0.96 | 99.04 |
| 2 | 1 | 1000 | Y | 14 | 53 | 0.78 | 99.22 |
| 3 | 1 | 1000 | Y | 14 | 50 | 0.96 | 99.04 |
| 4 | 1 | 1000 | Y | 14 | 45 | 0.95 | 99.05 |
| Note: | |||||||
| This set of recrystallizations were done on the same crude mixture used for Table 10, coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). However HPLC analysis of crude gave an approximate R/S ratio of 95.3/4.7. No Trans isomer was seen in the recrystallized mixture | |||||||
In yet another preferred embodiment, the 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or general formula (III) produced or formed in step (a) in accordance with the first, second, third, fourth, seventh, eighth and tenth aspects, is in the form of a conglomerate. The ability of these compounds to form conglomerates is surprising when taking into consideration that only 5% to 10% of racemates belong to the conglomerate forming group (Lorenz, H., et. al., Journal of the University of Chemical Technology and Metallurgy (2007) 42(1): 5-16).
Preferably the desired enantiomer which is obtained by any one of the processes according to the first, second, third, fourth, sixth, seventh, eighth and tenth aspects of the invention does not comprise any detectable amount of an undesired isomer.
Deprotection
Having coupled benzoyl cytosine to BOMO, the final step of the synthesis is the removal of the benzoyl protecting groups to obtain the debenzoylated product, for example compound (17) as shown in Scheme 5.
Suitable deprotection methods include: catalytic NaOMe/MeOH, Methanolic Ammonia, and Aqueous Ammonia in Methanol.
The sodium methoxide mediated hydrolysis was investigated first. This method deprotects quantitatively, however requires an aqueous workup to get rid of the salts non-chromatographically. Therefore as the final products, such as compound (17), may possess some water solubility, the workup reduces the yield. The methanolic ammonia method was also investigated. Methanolic ammonia again cleanly deprotected the molecule after overnight stirring, and after removal of the solvent, slurrying in acetone removed the more lipophilic by-products and yielded the product very cleanly. The reaction was equally successful whether the starting material were RR or SS (Table 14, experiments 2, 3, 4). Alternatively, it was found that aqueous ammonia in methanol could also be used. Deprotection using this method is slower but is clean however this involves the removal of water and thus is less convenient in larger scale than methanolic ammonia.
| TABLE 14 | ||
| Experiment | Method | Product Yield |
| 1 | NaOMe (0.1 eq)/MeOH | 61% (8 g scale) (for “RR” cis) |
| 2 | Methanolic Ammonia | 85% (2.2 g scale) (for “RR” cis) |
| 3 | Methanolic Ammonia | 94% (15 g scale) (for “RR” cis) |
| 4 | Methanolic Ammonia | 88% (1 g scale) (for “SS” cis) |
| 5 | Aq Ammonia in | 86% (3 g scale) (for “RR” cis) |
| Methanol | ||
Compounds
In a preferred embodiment of the fifth aspect of the invention, there is provided novel 2-substituted 4-substituted 1,3-oxathiolane derivatives. The compounds of general formula VIII and IX wherein R2, R3, R4 and R5 are as previously defined:
and are preferably selected from the group of compounds consisting of:
Particularly preferred are N-benzoyl derivatives of compounds of general formula VIII and IX, even more preferred are the N-benzoyl derivatives of formulas:
The preferred embodiments of the present invention will now be described without limitation by reference to the following Examples.
General
All reactions were conducted under a nitrogen atmosphere using oven dried glassware. 2-R and S-Benzoyloxymethyl-1,3-oxathiolane were supplied by Avexa. N-benzoylcytosine was purchased from Shanghai PI Chemicals. TMSI was synthesized in-house and was distilled after the synthesis. Triethylamine was distilled over KOH. The solvents were used without distillation. Low temperatures for reactions were maintained by using a Thermo-Neslab cryostat. The NMR spectra were run on a Varian High Field NMR spectrometer running at 400 MHz. Thin layer chromatography were performed on Machery-Nagel precoated plastic silica gel plates (0.22 mm). HPLC analyses were done on a Waters 510 HPLC system, with a Chiralpak AD, 25 cm×0.46 cm (ID) column, detecting at 254 nm. The solvent system was 20% MeOH in acetonitrile, running isochratically, at a flow rate of 2 mL/min.
Some abbreviations: Eq (equivalents), wrt (with respect to)
To a stirred mixture of 2-R-Benzoyloxymethyl-1,3-oxathiolane (118 g, 0.526 mol) and glacial acetic acid (47 g, 0.790 mol) in a 500 mL RB flask fitted with an air/water condenser, at 40° C., was added hydrogen peroxide (35% in water) (65 mL, 0.736 mol) in 4 portions at approximately 10 minute intervals. The initial additions are very exothermic. This was stirred at this temperature for 1 hour and at room temperature for 1 hour. The mixture was then transferred to a 1 L beaker and was diluted with dichloromethane (500 mL). While stirring, a solution of 10% sodium sulfite in water (500 mL) was added in small portions (initially vigorous reaction). The organic layer was separated and this was next stirred with an aqueous saturated sodium carbonate solution (500 mL) till there was no bubbling. The organic layer was separated, washed with brine and dried with magnesium sulfate. The resulting hazy colorless solution was filtered through celite to obtain a clear solution. This was evaporated to give the product as colorless viscous oil, which solidified to a white solid. This material was used for the next step in the synthesis without further purification. This material is a mixture of E/Z diastereomers of the ratio 2.4:1 (via NMR). Yield: 114 g (90%)
1H-NMR (CDCl3, 400 MHz): δ=8.05 (d), 7.9 (d), 7.5 (m), 7.4 (m), 4.6-4.8 (m), 4.4 (m), 4.1 (m), 3.2 (m), 3.1 (m), 2.7 (m) ppm. (NMR spectrum is complex due to the presence of E and Z diastereomers)
9.6 g of the E:Z mixture of 2-(R)-Benzoyloxymethyl-1,3-oxathiolane-S-oxide was dissolved in refluxing methanol (12 mL) and was allowed to come to room temperature slowly and allowed to stand overnight. The resulting colorless needle shaped crystals were filtered, washed with ice cold methanol (2 mL), dried. Yield: 3.0 g
1H-NMR (CDCl3, 400 MHz): δ=7.9 (d, 2H), 7.6 (m, 1H), 7.4 (m, 2H), 4.6-4.8 (m, 3H), 4.4 (m, 1H), 3.15 (m, 1H), 2.7 (m, 1H) ppm.
|
|
|
|
| Reagent | MW | Equivalents | Moles | Amount |
| 2-(R)-benzoyloxymethyl- | 240.3 | 1.0 | 0.062 | 15.0 | g |
| 1,3-oxathiolane-S-oxide | |||||
| (2) | |||||
| N-benzoylcytosine(1) | 215.1 | 1.0 | 0.062 | 13.4 | g |
| Iodotrimethylsilane | 200.1 | 3.1 | 0.193 | 38.8 | g, |
| d = 1.406 | 27.6 | mL | |||
| Triethylamine | 101 | 2.1 | 0.131 | 13.2 | g, |
| d = 0.726 | 18.2 | mL | |||
| Copper(II) | 134.5 | 0.1 | 0.006 | 0.84 | g |
| chloride(anhydrous) | |||||
| Dichloromethane | 250 | mL | |||
| Rz = C6H5CO | |||||
2-(R)-benzoyloxymethyl-1,3-oxathiolane-S-oxide (15.0 g, 0.063 mol) (optical purity of the starting 2-(R)-benzoyloxymethyl-1,3-oxathiolane R/S: 98.3/1.7) was dissolved in dichloromethane (250 mL) in a 500 mL 3-neck flask under nitrogen and this was cooled to −50° C. by means of a cryostat. To this triethylamine (9.6 mL, 0.069 mol, 1.1 equivalent) was added. This was followed by the dropwise addition of iodotrimethylsilane (18.7 mL, 0.131 mol, 2.1 equivalents) via a dropping funnel, at a rate such that the internal temperature remained below −40° C. The resulting light yellow solution was stirred for 30 minutes while maintaining the temperature at −50° C. Next, to the reaction mixture, triethylamine (8.7 mL, 0.062 mol, 1.0 equivalent) was added again followed by the repeat dropwise addition of iodotrimethylsilane (8.9 mL, 0.062 mol, and 1.0 equivalent). Next, oven dried anhydrous copper(II)chloride (0.84 g, 0.0062 mol) was added and after 5 minutes N-benzoylcytosine (13.4 g, 0.062 mol) was added. The resulting mixture was allowed to warm to 0° C. was stirred at this temperature overnight. After overnight stirring, the reaction was allowed to warm to room temperature and stirred at room temperature for 90 minutes. The reaction mixture was quenched with the addition of water (100 mL). This was stirred for 5 minutes, and was filtered through a celite plug. The plug was washed with additional dichloromethane (3×75 mL) and the combined filtrates were poured into a separating funnel. The organic layer was separated, washed sequentially with 5% ammonia in water (2×100 mL), 2% phosphoric acid (2×100 mL) and again with 5% ammonia (100 mL). The combined aqueous layers were re-extracted with dichloromethane (100 mL). The combined organic layers were then washed with IM sodium thiosulfate (100 mL). The resulting light yellow solution was dried with magnesium sulphate, filtered and evaporated to give a light yellow/brown thick oil 24.3 g (89% recovery). This crude mixture consisted of cis and trans combined coupled product at 75% purity (NMR) and with a cis/trans isomer ratio 2.45:1 (NMR)
Recrystallization with Entrainment
To the crude (R)-benzoyloxymethyl-4-(R,S)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane (10.3 g) in a 100 mL round bottom flask, was added 14.0 times (by volume) methanol (144.2 mL) and the mixture was refluxed till a clear solution could be seen. This was then allowed to cool with stirring while monitoring the temperature with a thermometer. When the temperature reached 53° C., the solution was seeded with 144 mg of pure 2-(R)-benzoyloxymethyl-4-(R)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane while vigorously stirring. Following the seeding, the rapidly crystallizing mixture was stirred vigorously overnight. The resulting crystallized product was then filtered, followed by washing with methanol (50 mL). Once all the mother liquor and the subsequent washing had passed through, the resulting crystallized white product was re-washed slowly with methanol (2×100 mL) and dried under vacuum. The resulting white crystalline solid on analyzing with NMR showed that it is >99% the cis isomer. Isolated yield, 4.4 g (44% yield for the recrystallization, based on the crude). Optical purity: RR/SS: 99.3/0.7.
Recrystallization without Entrainment
To the crude (R)-benzoyloxymethyl-4-(R,S)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane (8.0 g) in a 100 mL round bottom flask, was added approximately 14.0 times (by volume) methanol (112 mL) and the mixture was refluxed till a clear solution could be seen. This was then allowed to cool without stirring overnight. The resulting crystallized product was then filtered, followed by washing with methanol (50 mL). Once all the mother liquor and the subsequent washing had passed through, the resulting crystallized white product was re-washed slowly with methanol (2×100 mL) and dried under vacuum. The resulting white crystalline solid on analyzing with NMR showed that it is >99% the cis isomer. Isolated yield, 3.36 g (42% yield for the recrystallization, based on the crude). Optical purity: RR/SS: 98.1/1.9.
The comparative data provided in the following table shows that entrainment results in an increased yield of the RR enantiomer.
| Actual Enantiomer | |||
| Ratio R/S | |||
| (calculated | Recrystallization Method | ||
| based on purities | RR/SS ratio without | RR/SS ratio with | |
| Expt | of starting BOMOs) | Entrainment | Entrainment |
| 1 | 98.3/1.7 | 99.0-99.4/1.0-0.6 | 99.5-99.8/0.5-0.2 |
| 2 | 94.2/5.8 | 98.14/1.86 | 99.33/0.67 |
| 3 | 90.0/10.0 | 97.67/2.33 | 99.23/0.77 |
| 4 | 81.7/18.3 | 95.1/4.9 | 98.2/1.8 |
1H NMR(CDCl3): δ 8.9 (br s, 1H), 8.25 (d, 1H), 8.0 (d, 2H), 7.8 (d, 2H), 7.6 (m, 2H), 7.45 (m, 4H) 7.3 (poorly resolved d, 1H), 6.6 (d, 1H) 5.5 (t, 1H), 4.8 (m, 2H), 4.5 (d, 1H), 4.05 (dd, 1H)
HPLC Analysis: Column: Chiralpak AD 0.46×25 cm; Solvent System: acetonitrile/methanol 80:20; Flow rate: 2 mL/Min; Wavelength: 254 nm; Retention time for R,R isomer: 11.23 min.
|
|
|
|
| Reagent | Molecular Weight | Equivalents | Moles | Amount |
| 2-(R)-benzoyloxymethyl-1,3-oxathiolane | 240.3 | 1 | 0.050 | 12.0 | g |
| N-benzoylcytosine | 215.1 | 0.95 | 0.047 | 10.1 | g |
| Iodotrimethylsilane | 200.1 | 3 | 0.150 | 30.0 | g |
| d = 1.406 | 21.3 | mL | |||
| Triethylamine | 101 | 2.2 | 0.110 | 11.1 | g, |
| d = 0.726 | 15.3 | mL | |||
| Copper(II) chloride | 134.5 | 0.2 | 0.010 | 1.34 | g |
| Dichloromethane | 150 | mL | |||
| Bz = C6H5O | |||||
Procedure:
To 2-(R,S)-benzoyloxymethyl-1,3-oxathiolane (2) (12.0 g, 0.050 mol) was dissolved in dichloromethane in a 500 mL 3-neck flask and this was cooled to −50° C. To this triethylamine (15.3 mL, 0.110 mol) was added and followed by iodotrimethylsilane (21.4 mL, 0.150 mol) via a dropping funnel, dropwise, at a rate so that the internal temperature was between −30° C. and −50° C. The resulting light yellow solution was stirred for 45 minutes while maintaining the temperature between −40° C. and −50° C. Next, to the reaction mixture, was added copper(II)chloride (1.3 g, 0.010 mol) and after 5 more minutes was added N-benzoylcytosine (1)(10.1 g, 0.047 mol). The resulting mixture was stirred at −50° C. for 15 minutes and then was allowed to warm to 0° C. over 1 hour. The reaction mixture was stirred at this temperature overnight. After overnight stirring, the reaction was stirred at room temperature for 1 hour, cooled again in ice, quenched with the addition of water (100 mL) followed by 5% ammonia (100 mL). This was stirred for 5 minutes, diluted with dichloromethane (50 mL) and filtered through a celite plug. The plug was washed with additional dichloromethane (2×50 mL) and the combined filtrates were poured into a separating funnel. The organic layer was separated, washed with 2% phosphoric acid (2×60 mL) and again with 2.5% ammonia (2×100 mL). The combined aqueous layers were re-extracted with dichloromethane (100 mL). The combined organic layers were dried with magnesium sulphate, filtered and evaporated to give a light yellow/brown thick oil 17.8 g (86% recovery). This crude mixture consisted of cis (3) and trans (4) combined coupled product at 62% purity (NMR) and with a cis/trans isomer ratio 2.86:1 (NMR)
To the crude (R,S)-benzoyloxymethyl-4-(R,S)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane (17.8 g) in a 500 mL round bottom flask, was added 14.5 times (by volume) methanol (258 mL) and the mixture was refluxed till a clear solution could be seen. This was then allowed to cool to room temperature gradually and was left standing overnight. The resulting crystallized product was filtered, followed by washing with methanol (2×100 mL) and drying under vacuum. The resulting slightly coloured feathery crystalline solid on analysing with NMR showed that it is >99% the cis isomer (3). Isolated yield, 7.2 g (35% yield for the cis isomer).
1NMR(CDCl3): δ 8.5 (br s, 1H), 8.25 (d, 1H), 8.0 (d, 2H), 7.8 (d, 2H), 7.6 (m, 2H), 7.45 (m, 4H) 7.3 (poorly resolved d, 1H), 6.6 (d, 1H) 5.5 (t, 1H), 4.8 (m, 2H), 4.5 (d, 1H), 4.05 (dd, 1H)
HPLC Analysis: Column: Chiralpak AD, 25 cm×0.46 cm (ID); Solvent: 20% MeOH in acetonitrile; Flow rate: 1 ml/min; Wavelength: 254 nm; Enatiomeric Purity: >100:1
2-(R)-benzoyloxymethyl-1,3-oxathiolane-S-oxide (2.0 g, 0.0083 mol) (optical purity of the starting 2-(S)-benzoyloxymethyl-1,3-oxathiolane R/S: 12.1/87.9) was dissolved in dichloromethane (40 mL) in a 100 mL 3-neck flask under nitrogen and this was cooled to −50° C. by means of a cryostat. To this triethylamine (1.27 mL, 0.009 mol, and 1.1 equivalents) was added. This was followed by the dropwise addition of iodotrimethylsilane (2.5 mL, 0.017 mol, 2.1 equivalents) via a dropping funnel, at a rate such that the internal temperature remained below −40° C. The resulting light yellow solution was stirred for 30 minutes while maintaining the temperature at −50° C. Next, to the reaction mixture, triethylamine (1.15 mL, 0.0083 mol, 1.0 equivalent) was added again followed by the repeat dropwise addition of iodotrimethylsilane (1.2 mL, 0.0083 mol, and 1.0 equivalent). Next, oven dried anhydrous copper(II)chloride (0.11 g, 0.0008 mol) was added and after 5 minutes N-benzoylcytosine (1.79 g, 0.0083 mol) was added. The resulting mixture was allowed to warm to 0° C. was stirred at this temperature overnight. After overnight stirring, the reaction was allowed to warm to room temperature and stirred at room temperature for 90 minutes. The reaction mixture was next quenched with the addition of water (25 mL). This was stirred for 5 minutes, and was filtered through a celite plug. The plug was washed with additional dichloromethane (3×25 mL) and the combined filtrates were poured into a separating funnel. The organic layer was separated, washed sequentially with 5% ammonia in water (2×25 mL), 2% phosphoric acid (2×25 mL) and again with 5% ammonia (25 mL). The combined aqueous layers were re-extracted with dichloromethane (25 mL). The combined organic layers were then washed with IM sodium thiosulfate (250 mL). The resulting light yellow solution was dried with magnesium sulphate, filtered and evaporated to give a light yellow/brown thick oil 2.4 g (71% recovery). This crude mixture consisted of cis and trans combined coupled product at 69% purity (NMR) and with a cis/trans isomer ratio 2.4:1 (NMR)
Recrystallization with Entrainment
To the crude (S)-benzoyloxymethyl-4-(R,S)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane (2.4 g) in a 100 mL round bottom flask, was added approximately 14.0 times (by volume) methanol (34 mL) and the mixture was refluxed till a clear solution could be seen. This was then allowed to cool with stirring while monitoring the temperature with a thermometer. When the temperature reached 53° C., the solution was seeded with 34 mg of previously recrystallized 2-(S)-benzoyloxymethyl-4-(S)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane while vigorously stirring. Following the seeding, the rapidly crystallizing mixture was stirred vigorously overnight. The resulting crystallized product was then filtered, followed by washing with methanol (10 mL). Once all the mother liquor and the subsequent washing had passed through, the resulting crystallized white product was re-washed slowly with methanol (2×10 mL) and dried under vacuum. The resulting white crystalline solid on analyzing with NMR showed that it is >99% the cis isomer. Isolated yield, 0.96 g (40% yields for the recrystallization, based on the crude). Optical purity: RR/SS: 1.5/98.
Recrystallization without Entrainment
To the crude (S)-benzoyloxymethyl-4-(R,S)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane (13.95 g) in a 250 mL round bottom flask, was added approximately 14.0 times (by volume) methanol (194.6 mL) and the mixture was refluxed till a clear solution could be seen. This was then allowed to cool without stirring overnight. The resulting crystallized product was then filtered, followed by washing with methanol (50 mL). Once all the mother liquor and the subsequent washing had passed through, the resulting crystallized white product was re-washed slowly with methanol (50 mL) and dried under vacuum. The resulting white crystalline solid on analyzing with NMR showed that it is >99% the cis isomer. Isolated yield, 4.8 g (34% yield for the recrystallization, based on the crude). Optical purity: RR/SS: 2.2/97.8.
Variables Affecting Entrainment
Experiments were done with crude 2-(R)-benzoyloxymethyl-4-(R)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane.
Effect of Time
Each sample came from a reaction where the starting ratio for the BOMO was 97(R)/3(S) (The R/S ratio of the crude was not done for these samples). The crude was recrystallized by dissolving while refluxing in 14 volumes of methanol. For entrainment 14 mg seeds (pure R,R) per gram of crude were used. Seeding was done at a temperature between 55° C. and 56° C. After the specified time, the crystals were filtered, washed with methanol, dried, and analyzed with HPLC. The results are shown in the following table.
| Optical Purity | ||
| Time allowed | Recrystallization | Recrystallization | |
| for | with seeding | without seeding | |
| Experiment | crystallization | (14 mg/g crude) | or stirring |
| 1 | 1.5 hrs | 98.3/0.7 | 98.4/1.6 |
| 2 | 3 hrs | 98.4/1.6 | 99.4/1.6 |
| 3 | 4 days | 98.6/1.4 | 99.5/0.5 |
Effect of Stirring and Seeding
Each sample came from a reaction where the starting ratio for the BOMO was 82 (R)/18 (S). The crude was recrystallized by dissolving while refluxing in 14 volumes of methanol. Next this is allowed to cool with stirring (at the specified rate) or without stirring, while monitoring the temperature. At the temperature of 55° C., the stirred mixture is seeded with Pure ‘R,R’ isomer or not seeded and stirred overnight while allowing the temperature to come to room temperature. The crystallized mixture is then filtered, washed with methanol and analyzed via HPLC. The results are shown in the following table.
| CONDITIONS | ||
| Seeds |
| Amounts of | ||||||
| Standing | Rate of | Seeds | Temperature | |||
| time | Stirring | Seeded | (mg of seeds/g | of seeding | RESULTS |
| Expt # | (days) | (rpm) | (Yes/No) | crude) | ° C. | S,S | R,R |
| 1 | 1 | 1000 | Y | 14 | 55 | 0.83 | 99.17 |
| 2 | 1 | 0 | Y | 14 | 55 | 1.71 | 98.29 |
| 3 | 1 | 1000 | N | — | — | 1.45 | 98.55 |
| 4 | 1 | 0 | N | — | — | 1.81 | 98.19 |
| 5 | 3 | 1000 | Y | 14 | 55 | 0.68 | 99.32 |
| Note: | |||||||
| This set of recrystallizations were done on a crude mixture coming from a reaction where the starting BOMO R/S ratio R/S ratio: 82:18. However HPLC analysis of crude gave an approximat R/S ratio of 95.3/4.7. No Trans isomer was seen in the recrystallized mixture | |||||||
Effect of Temperature
Each sample came from a reaction where the starting ratio for the BOMO was 82 (R)/18 (S). The crude was recrystallized by dissolving while refluxing in 14 volumes of methanol. Next this is allowed to cool with stirring (at 1000 rpm) or without stirring, while monitoring the temperature. At the specified temperature of 55° C., the stirred mixture was seeded with Pure ‘R,R’ isomer stirred overnight while allowing the temperature to come to room temperature. The crystallized mixture is then filtered, washed with methanol and analyzed via HPLC. The results are shown in the following table.
| CONDITIONS | ||
| Seeds |
| Amounts of | ||||||
| Standing | Rate of | Seeds | Temperature | |||
| time | Stirring | Seeded | (mg of seeds/g | of seeding | RESULTS |
| Expt | (days) | (rpm) | (Yes/No) | crude) | ° C. | S,S | R,R |
| 1 | 1 | 1000 | Y | 14 | 55 | 0.96 | 99.04 |
| 2 | 1 | 1000 | Y | 14 | 53 | 0.78 | 99.22 |
| 3 | 1 | 1000 | Y | 14 | 50 | 0.96 | 99.04 |
| 4 | 1 | 1000 | Y | 14 | 45 | 0.95 | 99.05 |
| Note: | |||||||
| This set of recrystallizations were done on the same crude mixture used for Table 16, coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). However HPLC analysis of crude gave an approximate R/S ratio of 95.3/4.7. No Trans isomer was seen in the recrystallized mixture | |||||||
Recrystallization in Mixed Solvent Systems
All recrystallizations were seeded at 53° C., 14 mg of seed/g crude, stirred at 1000 rpm, with ×14 volumes of solvent. Recrystallizations were done on a crude mixture coming from a reaction where the starting BOMO R/S ratio was 82:18. HPLC analysis of crude gave an approximate crude R/S ratio of 86/14. As previously discussed, when R/S ratio decreases, specially below 90:10, there is a propensity for trans isomer to also crystallize (Table 11). Thus In this set of experiments, we did see the trans isomer uniformly about 10-12%. Therefore the observed RR/SS ratio was corrected for the presence of RR and SS trans isomers. The results are shown in the following table.
| Corrected | ||||
| C/T | Observed | Optical | ||
| Expt | Recrystallization Solvent | Ratio | Purity | Purity |
| # | System | (NMR) | S,S | R,R | SS | RR |
| 1 | Methanol 100% | 88/12 | 2.33 | 97.67 | 2.65 | 97.35 |
| 2 | Methanol 95%, Ethanol 5% | 88/12 | 2.68 | 97.32 | 3.06 | 96.94 |
| 3 | Methanol 95%, 1-Propanol | 89/11 | 2.26 | 97.74 | 2.53 | 97.47 |
| 5% | ||||||
| 4 | Methanol 95%, 2-Propanol | 89/11 | 2.97 | 97.03 | 3.33 | 96.67 |
| 5% | ||||||
| 5 | Methanol 95%, 1-Butanol | 88/12 | 2.52 | 97.48 | 2.82 | 97.18 |
| 5% | ||||||
| 6 | Methanol 95%, 1-Pentanol | 88/12 | 2.95 | 97.05 | 3.36 | 96.64 |
| 5% | ||||||
| 7 | Methanol 95%, 1-Hexanol | 88/12 | 2.57 | 97.43 | 3.93 | 96.07 |
| 5% | ||||||
| 8 | Methanol 99%, Water 1% | 90/10 | 2.98 | 97.02 | 3.21 | 96.79 |
| 9 | Methanol 95%, Water 5% | 87/13 | 4.6 | 95.4 | 5.24 | 94.76 |
| Note: | ||||||
| This set of recrystallization were done on a crude mixture coming from a reaction where the starting BOMO R/S ratio was 80/20 (actual R/S ratio: 82:18). HPLC analysis of crude gave an approximate crude R/S ratio of 86/14). | ||||||
2-(R)-benzoyloxymethyl-4-(R)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane (15 g, 0.028 mol) was dissolved in a methanolic ammonia (approximately 2M) solution (250 mL). The initial slurry was stirred overnight. After overnight stirring, the resulting clear solution was filtered through celite, evaporated to dryness and slurried in acetone (100 mL). This yielded off-white powdery solid which was filtered and washed with acetone (2×25 mL), and dried to yield the product. 6.5 g (94%).
1H NMR(DMSO): δ 7.8 (d, 1H), 7.0-7.2 (broad d, 2H), 6.3 (d, 1H), 5.7 (d, 1H), 5.3 (t, 1H) (OH peak—not always resolved), 5.1 (t, 1H), 4.4 (d, 1H), 3.9 (m, 1H), 3.7 (m, 2H), OH peak not resolved
|
|
|
|
| Molecular | ||||
| Reagent | Weight | Equivalents | Moles | Amount |
| 2-(R)-benzoyloxy- | 437.4 | 1 | 0.007 | 3.3 | g |
| methyl-4- | |||||
| (R)-(N-benzoylcytosin-1- | |||||
| yl)-1,3-oxathiolane | |||||
| NaOMe (prepared | 54 | 0.11 | 0.0008 | 0.43 | g |
| from Na | |||||
| and methanol) | |||||
| Dichloromethane | 8 | mL | |||
| Methanol | 10 | mL | |||
Procedure:
2-(R)-benzoyloxymethyl-4-(R)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane (3.3 g, 0.007 mol) was dissolved in a mixture of dichloromethane (8 mL) and methanol (10 mL) with heating. To this was added sodium methoxide (0.043 g, 0.0008 mol) in methanol (2 mL) and the mixture was stirred overnight. After overnight stirring, the mixture was evaporated and was chromatographed on a silica gel column (4×18 cm) eluting using a gradient of 20-50% methanol in Ethyl acetate. Combination and evaporation of the appropriate fractions yielded 1.5 g (88% yield) of the product (5) as an off white powder.
1H NMR(DMSO): δ 7.8 (d, 1H), 7.0-7.2 (broad d, 2H), 6.3 (d, 1H), 5.7 (d,1 H), 5.1 (t, 1H), 4.4 (d, 1H), 3.9 (m, 1H), 3.7 (m, 2H), OH peak not resolved
2-(S)-benzoyloxymethyl-4-(S)—(N-benzoylcytosin-1-yl)-1,3-oxathiolane (1.0 g, 0.0022 mol) was dissolved in a methanolic ammonia (approximately 2M) solution (20 mL). The initial slurry was stirred overnight. After overnight stirring, the resulting clear solution was evaporated to dryness and slurried in acetone (20 mL). This yielded off-white powdery solid which was filtered and washed with acetone (2×10 mL), and dried to yield the product. 0.47 g (88%).
1H NMR(DMSO): δ 7.8 (d, 1H), 7.0-7.2 (broad d, 2H), 6.3 (d, 1H), 5.7 (d,1 H), 5.3 (t, 1H) (OH peak—not always resolved), 5.1 (t, 1H), 4.4 (d, 1H), 3.9 (m, 1H), 3.7 (m, 2H), OH peak not resolved
2-(R)-benzoyloxymethyl-1,3-oxathiolane (5.0 g, 0.021 mol) was dissolved in dichloromethane (100 mL) in a 500 mL 3-neck flask under nitrogen and to this triethylamine (6.08 mL, 0.044 mol) was added. The solution was cooled to −50° C. next and iodotrimethylsilane (9.22 mL, 0.065 mol) was added to this via a dropping funnel dropwise, at a rate, the internal temperature did not rise above −40° C. The resulting light yellow solution was stirred for 1 hour, while maintaining the temperature at −50° C. Next, to the reaction mixture, copper(II)chloride (0.28 g, 0.021 mol) was added followed by N-acetylcytosine (5.0 g, 0.021 mol). The resulting mixture was stirred at −50° C. for 15 minutes, allowed to warm to 0° C. and stirred at this temperature overnight. After overnight stirring, the reaction was stirred at room temperature for 1 hour, quenched with the addition of water (50 mL) immediately followed by 5% ammonia (100 mL). This was stirred well for 10 minutes, filtered through a celite plug (8×3 cm). The flask and the plug were washed with additional dichloromethane (100 mL, 2×50 mL). The combined, clear filtrates were poured into a separating funnel and the organic layer was separated out. The organic layer was then washed with 2% phosphoric acid (100 mL). The combined aqueous layers were re-extracted with dichloromethane (100 mL). The combined organic layers were dried with magnesium sulphate, filtered and evaporated to give a light yellow/light brown viscous oil 6.8 g (92% recovery).
NMR analysis of the crude gave the following data: Extent of the reaction (NMR estimated purity of the total coupled product): 73%; C/T ratio: 2.37:1; Amount of olefin by-product (with respect to the total coupled product): 8%
|
|
|
|
| Molecular | Equiva- | |||
| Reagent | Weight | lents | Moles | Amount |
| 2-(R,S)-benzoyloxy- | 240.3 | 1.0 | 0.040 | 9.6 | g |
| methyl- | |||||
| 1,3-oxathiolane | |||||
| N-benzoylcytosine | 215.1 | 1.0 | 0.040 | 9.3 | g |
| Iodotrimethylsilane | 200.1 | 3.1 | 0.124 | 24.9 | g |
| d = 1.406 | 17.7 | mL | |||
| Triethylamine | 101 | 2.2 | 0.088 | 8.9 | g, |
| d = 0.726 | 12.2 | mL | |||
| Copper(II) chloride | 134.5 | 0.2 | 0.080 | 1.08 | g |
| Dichloromethane | 150 | mL | |||
| Bz = C6H5CO | |||||
Procedure:
To a mixture of 2-(R)-benzoyloxymethyl-1,3-oxathiolane and 2-(S)-benzoyloxymethyl-1,3-oxathiolane (9.6 g, 0.040 mol) was dissolved in dichloromethane in a 500 mL 3-neck flask and this was cooled to −50° C. To this triethylamine (12.2 mL, 0.088 mol) was added and followed by iodotrimethylsilane (17.7 mL, 0.124 mol) via a dropping funnel, dropwise, at a rate so that the internal temperature was between −35° C. and −50° C. The resulting light yellow solution was stirred for 60 minutes while maintaining the temperature between −40° C. and −50° C. Next, to the reaction mixture, was added copper(II)chloride (1.3 g, 0.010 mol) and after 5 more minutes was added N-benzoyl-5-fluorocytosine (9.3 g, 0.040 mol). The resulting mixture was stirred at −50° C. for 15 minutes and then was allowed to warm to 0° C. over 1 hour. The reaction mixture was stirred at this temperature overnight. After overnight stirring, the reaction was stirred at room temperature for 1 hour, cooled again in ice, quenched with the addition of saturated sodium bicarbonate (75 mL). This was stirred for 5 minutes, diluted with dichloromethane (50 mL) and filtered through a celite plug. The plug was washed with additional dichloromethane (2×50 mL) and the combined filtrates were poured into a separating funnel. The organic layer was separated, washed 5% ammonia (100 mL), 2% phosphoric acid (2×60 mL) and again with 5% ammonia (100 mL). The combined aqueous layers were re-extracted with dichloromethane (100 mL). The combined organic layers were dried with magnesium sulphate, filtered and evaporated to give a light yellow/brown thick oil 14.6 g (80% recovery). This crude mixture consisted of cis (R,R and S,S) and trans (S,R and R,S) combined coupled product at 55% purity (NMR) and with a cis:trans isomer ratio 2.65:1 (NMR).
To the crude (R)-benzoyloxymethyl-4-(R,S)—(N-benzoyl-5-fluorocytosin-1-yl)-1,3-oxathiolane (14.6 g) in a 500 mL round bottom flask, was added 10 times (by volume) methanol (146 mL) and the mixture was refluxed till a clear solution could be seen. This was hot filtered and then allowed to cool to room temperature gradually and was left standing overnight. The resulting crystallized product was filtered, followed by washing with methanol (2×100 mL) and drying under vacuum. The resulting slightly coloured powdery crystalline solid on analysing with NMR showed that it is >98% the cis isomer. Isolated yield, 3.5 g (19% yield for the cis isomer(7)).
1H NMR(DMSO): δ 7.95 (m, 3H), 7.75 (m, 2H), 7.6 (m, 2H), 7.6-7.4 (m, 4H), 6.22 (dd, 1H), 5.43 (t, 1H), 4.7 (m, 2H), 4.55 (d, 1H), 3.95 (dd, 1H)
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications which fall within the spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
-
- 1. Belleau et. al., Bioorg. Med. Chem. Lett. (1993) Vol. 3, No. 8, 1723-1728.
- 2. Taylor et. al., Antiviral Chem. Chemother. (2000) Vol. 11, No. 4, 291-301.
- 3. Stoddart et. al., Antimicrob. Agenst Chemother. (2000) Vol, 44, No. 3, 783-786.
- 4. Mansour et. al., J. Med. Chem., (1995) Vol. 38, No. 1: 1-4.
- 5. Nucleosides and Nucleotides (1995) 14(3-5): 627-735.
- 6. Caputo et. al. Eur. J. Org. Chem. (1999) Vol. 6: 1455-1458.
- 7. J. Jacques, A. Collet & S. H. Wilen “Enantiomers, Racemates and Resolutions” by (John Wiley & Sons, 1981).
- 8. Storer et. al., Nucleosides & Nucleotides (1993) 12(2): 225-236.
- 9. Lorenz, H., et. al., Journal of the University of Chemical Technology and Metallurgy (2007) 42(1): 5-16.
- 10. Greene, T. W. and Wuts, P. G. M “Protective groups in organic synthesis” (3rd Edition) 1999 John Wiley & Sons Inc.
Claims (42)
1. A process for producing a compound of general formula (II) comprising the steps of:
(a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) and (III):
wherein
R2 is C(O)phenyl;
R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
R5 is H, Br, Cl, F, I or CF3; and
(b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
3. A process for producing a compound of general formula (VI) comprising the steps of:
(a) forming a 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) and (III):
wherein
R2 is C(O)phenyl;
R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
R5 is H, Br, Cl, F, I or CF3;
(b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
(c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
5. The process according to claim 1 , wherein R5 is H or F.
6. A process for producing a compound of general formula (VI) or (VII) from a compound of general formula (VIII) or (IX) respectively, comprising the step of:
(a) deprotecting a compound of general formula (VIII) or (IX) to produce a compound of general formula (VI) or (VII) respectively:
7. The process according to claim 6 , wherein R5 is H or F.
8. A process for producing a compound of general formula (II) comprising the steps of:
(a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) and (III):
wherein
R2 is C(O)phenyl;
R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
R5 is H, Br, Cl, F, I or CF3; and
R10 is a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6alkylaryl; and
wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee; and
(b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
9. A process for producing a compound of general formula (VI) comprising the steps of:
(a) reacting a silylated base of general formula (X) with a 1,3-oxathiolane of general formula (V) to produce a compound of general formula (II) and (III):
wherein
R2 is C(O)phenyl;
R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H;
R5 is H, Br, Cl, F, I or CF3; and
R10 is a silyl protecting group of general formula SiR7R8R9 wherein R7, R8 and R9 are each independently selected from C1-6alkyl, aryl or C1-6alkylaryl;
wherein the 1,3-oxathiolane of general formula (V) is the (R)-enantiomer in at least 60% ee;
(b) selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols; and
(c) deprotecting the compound of general formula (II) to produce a compound of general formula (VI):
10. A process for separating a compound of general formula (II) from a compound of general formula (III) comprising the steps of:
(a) providing a mixture of 2-substituted 4-substituted 1,3-oxathiolanes of general formula (II) and (III):
wherein
R2 is C(O)phenyl;
R3 and R4 are each individually selected from H or benzoyl, provided that when R3 is H, R4 is not H and when R4 is H, R3 is not H; and
R5 is H, Br, Cl, F, I or CF3; and
(b) separating the compound of general formula (II) from the compound of general formula (III) by selective recrystallisation of the compound of general formula (II) from a solvent wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
11. The process according to claim 2 , wherein 1,3-oxathiolane of general formula (V) is greater than 95% ee.
12. The process according to claim 11 wherein the 1,3-oxathiolane of general formula (V) is greater than 99% ee.
13. The process according to claim 1 , wherein the solvent is C1-6alcohol selected from the group consisting of methanol (MeOH), ethanol (EtOH), propanol and butanol.
14. The process according to claim 13 wherein the C1-6alcohol is methanol.
15. The process according to claim 1 , wherein the solvent is a mixture of C1-6alcohols comprising MeOH.
16. The process according to claim 15 wherein the mixture of C1-6alcohols is in the ratio of 90:10 MeOH:C2-6alcohol.
17. The process according to claim 15 wherein the ratio is 95:5 MeOH:C2-6alcohol.
18. The process according to claim 13 , wherein the solvent contains no more than about 5% water.
19. The process according to claim 1 , wherein the selective recrystallisation step (b) is repeated at least once.
20. The process according to claim 1 , wherein the selective recrystallisation step (b) is an entrainment or a cyclic entrainment process.
21. The process according to claim 20 wherein the entrainment or cyclic entrainment process comprises seeding with an R,R-enantiomer.
22. The process according to claim 21 wherein the seeding is performed at a temperature less than or about 55° C.
23. The process according to claim 1 , wherein the 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or general formula (III) produced or formed in step (a) is in the form of a conglomerate.
24. The process according to claim 1 , wherein the 2-substituted 4-substituted 1,3-oxathiolane of general formula (II) or general formula (III) produced or formed does not comprise any detectable amount of an undesired isomer.
26. The compound according to claim 25 , wherein R5 is H or F.
28. A compound of general formula (VIII) or (IX):
29. The compound of claim 28 , wherein the solvent is C1-6alcohol or mixtures of C1-6alcohols.
30. The compound of claim 28 , wherein R5 is H or F.
32. The compound of claim 29 , wherein the solvent is C1-6alcohol selected from the group consisting of methanol (MeOH), ethanol (EtOH), propanol and butanol.
33. The compound of claim 32 wherein the C1-6alcohol is methanol.
34. The compound of claim 29 , wherein the solvent is a mixture of C1-6alcohols comprising MeOH.
35. The compound of claim 34 wherein the mixture of C1-6alcohols is in the ratio of 90:10 MeOH:C2-6alcohol.
36. The compound of claim 34 wherein the ratio is 95:5 MeOH:C2-6alcohol.
37. The compound of claim 29 , wherein the solvent contains no more than about 5% water.
38. The compound of claim 28 , wherein the selective recrystallisation is an entrainment or a cyclic entrainment process.
39. The compound of claim 38 wherein the entrainment or cyclic entrainment process comprises seeding with an R,R-enantiomer.
40. The compound of claim 39 wherein the seeding is performed at a temperature less than or about 55° C.
41. The compound of claim 28 , wherein the compound is in the form of a conglomerate.
42. The compound of claim 28 , wherein the compound does not comprise any detectable amount of an undesired isomer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/680,137 US8318934B2 (en) | 2007-09-28 | 2008-09-26 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007905335 | 2007-09-28 | ||
| AU2007905335A AU2007905335A0 (en) | 2007-09-28 | A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes | |
| US98125207P | 2007-10-19 | 2007-10-19 | |
| PCT/AU2008/001433 WO2009039582A1 (en) | 2007-09-28 | 2008-09-26 | A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes |
| US12/680,137 US8318934B2 (en) | 2007-09-28 | 2008-09-26 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20100305321A1 US20100305321A1 (en) | 2010-12-02 |
| US8318934B2 true US8318934B2 (en) | 2012-11-27 |
Family
ID=40510677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/680,137 Expired - Fee Related US8318934B2 (en) | 2007-09-28 | 2008-09-26 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8318934B2 (en) |
| EP (1) | EP2190839B1 (en) |
| JP (1) | JP5577251B2 (en) |
| KR (1) | KR101374635B1 (en) |
| CN (1) | CN101842370B (en) |
| AU (1) | AU2008303073B2 (en) |
| BR (1) | BRPI0817481A2 (en) |
| CA (1) | CA2700653C (en) |
| ES (1) | ES2542154T3 (en) |
| IL (1) | IL204596A (en) |
| IN (1) | IN2015DN02599A (en) |
| MX (1) | MX2010003521A (en) |
| NZ (1) | NZ584193A (en) |
| RU (1) | RU2494098C2 (en) |
| WO (1) | WO2009039582A1 (en) |
| ZA (1) | ZA201001951B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
| US20060199786A1 (en) | 2005-03-07 | 2006-09-07 | Alex Cimpoia | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl) -1,3-oxathiolane or pharmaceutically acceptable salts thereof |
| WO2006096954A1 (en) | 2005-03-14 | 2006-09-21 | Shire Biochem Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69921829T2 (en) * | 1998-08-12 | 2005-10-27 | Gilead Sciences, Inc., Foster City | PROCESS FOR THE PREPARATION OF 1,3-OXATHOLO NUCLEOSIDE |
| HRP20031021B1 (en) * | 2001-06-15 | 2007-09-30 | Shire Biochem Inc. | STEREOSELECTIVE PROCEDURE FOR MAKING NUCLEOID ANALOGS |
| KR20070080108A (en) * | 2006-02-06 | 2007-08-09 | 주식회사종근당 | Optical isomer separation method of racemic derivative with asymmetric carbon at alpha position of nitrogen |
-
2008
- 2008-09-26 AU AU2008303073A patent/AU2008303073B2/en not_active Ceased
- 2008-09-26 MX MX2010003521A patent/MX2010003521A/en active IP Right Grant
- 2008-09-26 NZ NZ584193A patent/NZ584193A/en not_active IP Right Cessation
- 2008-09-26 WO PCT/AU2008/001433 patent/WO2009039582A1/en active Application Filing
- 2008-09-26 ES ES08800068.2T patent/ES2542154T3/en active Active
- 2008-09-26 JP JP2010526111A patent/JP5577251B2/en not_active Expired - Fee Related
- 2008-09-26 CN CN200880113701.9A patent/CN101842370B/en not_active Expired - Fee Related
- 2008-09-26 RU RU2010116776/04A patent/RU2494098C2/en not_active IP Right Cessation
- 2008-09-26 IN IN2599DEN2015 patent/IN2015DN02599A/en unknown
- 2008-09-26 BR BRPI0817481A patent/BRPI0817481A2/en not_active IP Right Cessation
- 2008-09-26 EP EP08800068.2A patent/EP2190839B1/en not_active Not-in-force
- 2008-09-26 US US12/680,137 patent/US8318934B2/en not_active Expired - Fee Related
- 2008-09-26 KR KR1020107009176A patent/KR101374635B1/en not_active Expired - Fee Related
- 2008-09-26 CA CA2700653A patent/CA2700653C/en not_active Expired - Fee Related
-
2010
- 2010-03-18 IL IL204596A patent/IL204596A/en not_active IP Right Cessation
- 2010-03-18 ZA ZA2010/01951A patent/ZA201001951B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
| US20060199786A1 (en) | 2005-03-07 | 2006-09-07 | Alex Cimpoia | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl) -1,3-oxathiolane or pharmaceutically acceptable salts thereof |
| WO2006096954A1 (en) | 2005-03-14 | 2006-09-21 | Shire Biochem Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
Non-Patent Citations (3)
| Title |
|---|
| Brooks et al., The Separation of Steroid Alcohols by Chromatography of their Benzoates on Alumina, W. 12, Postgraduate Medical School, 212-217 (1952). * |
| International Search Report for Application No. PCT/AU2008/001433, dated Apr. 2, 2009. |
| Jurgen Fuhrhop & Gustav Penzlin, Organic Synthesis: Concepts, Methods, Starting Materials, 216 (VCH Publishers, Inc. 1994) (1983). * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL204596A (en) | 2013-08-29 |
| KR20100075964A (en) | 2010-07-05 |
| CA2700653C (en) | 2013-11-26 |
| RU2494098C2 (en) | 2013-09-27 |
| ES2542154T3 (en) | 2015-07-31 |
| RU2010116776A (en) | 2011-11-10 |
| WO2009039582A1 (en) | 2009-04-02 |
| CA2700653A1 (en) | 2009-04-02 |
| KR101374635B1 (en) | 2014-03-14 |
| MX2010003521A (en) | 2010-04-27 |
| JP2010540467A (en) | 2010-12-24 |
| IL204596A0 (en) | 2010-11-30 |
| CN101842370B (en) | 2014-02-19 |
| NZ584193A (en) | 2011-07-29 |
| JP5577251B2 (en) | 2014-08-20 |
| ZA201001951B (en) | 2011-05-25 |
| EP2190839A4 (en) | 2011-10-26 |
| AU2008303073B2 (en) | 2012-08-09 |
| IN2015DN02599A (en) | 2015-09-18 |
| US20100305321A1 (en) | 2010-12-02 |
| AU2008303073A1 (en) | 2009-04-02 |
| BRPI0817481A2 (en) | 2017-05-16 |
| CN101842370A (en) | 2010-09-22 |
| EP2190839A1 (en) | 2010-06-02 |
| EP2190839B1 (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100241842B1 (en) | Method for Diastereoselective Synthesis of Nucleoside Homologs | |
| US9902751B2 (en) | Process for the preparation of empagliflozin | |
| JP5485140B2 (en) | Process for producing ethynylthymidine compound starting from 5-methyluridine | |
| US8304540B2 (en) | Process for stereoselective synthesis of lamivudine | |
| JP2017522343A (en) | Synthesis of phosphoramidates | |
| CZ293942B6 (en) | Method for the increase of yield of one of alcohol enantiomers | |
| EP2225232B1 (en) | Process for the preparation of substituted 1,3-oxathiolanes | |
| US8318934B2 (en) | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes | |
| US7230100B2 (en) | Stereoselective method for the preparation of nucleosides | |
| CA2786227A1 (en) | Improved process for nucleosides | |
| Nguyen-Ba et al. | Short synthesis of 2, 4-disubstituted 1, 3-oxathiolane and 1, 3-dithiolane cytosine nucleosides: Facile introduction of a 4-benzoate group using benzoyl peroxide | |
| EP2358708B1 (en) | Optical resolution of substituted 1.3-oxathiolane nucleosides | |
| CN1746169A (en) | Preparation method of 4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AVEXA LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EPA, WIDANAGAMAGE RUWANSIRI;MARCUCCIO, SEBASTIAN MARIO;DEADMAN, JOHN JOSEPH;REEL/FRAME:029102/0737 Effective date: 20100408 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20161127 |
















































































